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ABSTRACT
EFFECTS OF CONJUGATED LINOLEIC ACID (CLA) ON SKELETAL MUSCLE
METABOLISM
SEPTEMBER 2015
YOO KIM, B.A., KOREA UNIVERSITY, KOREA
M.A., KOREA UNIVERSITY, KOREA
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Yeonhwa Park

Although it is well known that increased physical activity can help reduce incidences of
obesity, physical activity can be influenced by complex issues, making it difficult to use universal
means to control obesity. Recent discoveries of the effects of exercise at the cellular level opened
up the unique opportunity to develop compounds with ‘exercise-like’ effects. In fact, CLA has
been shown to promote voluntary activity and endurance capacity in mice. Thus, the purpose of
these studies is to determine the mechanisms of conjugated linoleic acid on muscle metabolism
via the modulation of biochemical events including mitochondrial biogenesis and the alternation
of fiber composition in skeletal muscle in order to develop preventive strategies for obesity.
Based on in vitro fundamental mechanism studies, we observed that CLA stimulated
mitochondrial biogenesis by signaling the up-regulation of peroxisome proliferator-activated
receptor γ coactivator 1α (PGC-1α) and related biomarkers involved in muscle metabolism. These
new findings provided the opportunity to consider CLA as a candidate for bioactive compound
mimicking exercises. We conducted additional animal studies, which were organized into three
parts. The first part was an adult obesity study with the nescient basic helix loop helix 2 (Nhlh2)
gene knockout mice, which are the genetically induced inactivity adult-onset obesity model.
Moreover, the study was designed for childhood obesity with post-weaning Nhlh2 mice under the
pre-obese state. Lastly, this was an exercise model, which divided normal mice into four groups
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according to diet and training, such as sedentary or exercise regimes. Consequently, these three
studies have shown that CLA enhances voluntary activity and endurance capacity. Additionally,
there were increases of muscle mass and decreases of body fat mass through modulating muscle
metabolism by stimulating mitochondrial biogenesis, inducing genes of muscle fibers, and
enhancing lipid metabolism based on the AMP-activated protein kinase (AMPK) signaling
pathway. Particularly, the PPARδ-mediated pathway plays a central role in overall skeletal
muscle metabolism. The current results suggest that CLA acts as a potential exercise-mimetic,
resulting in improved physical activity, which can also support its function of regulating body fat.
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CHAPTER 1
INTRODUCTION
Around 40-60% of the world population suffers from obesity and related chronic
diseases including type II diabetes, cardiovascular disease, metabolic syndrome and certain types
of cancer. Calorie restriction accompanied with physical activity leading to increased energy
expenditure is elucidated as the most effective strategy to reduce obesity.1,2 Although increased
physical activity contributes to various health benefits for attenuating an incidence of obesity as
well as its associated pathologies, complex social, environmental, physiological and
psychological factors can affect the subject’s physical activity. Thus, it is difficult to simply use
physical activity as universal means to control obesity. However, over the last decade, a growing
body of evidence has shed light on the unique importance to intervene and develop drugs or
dietary components as an exercise mimetic to demonstrate the alteration of molecular targets by
exercise.3-6
On a weight basis, skeletal muscle tissue is the largest portion of total body mass in the
normal human body, excluding obese individuals. Skeletal muscle is one of the most
metabolically demanding tissues, which accounts for almost half of all energy expenditure, as
well as three-fourths of all glucose disposal. In addition, skeletal muscle has a unique metabolic
flexibility in energy metabolism, responding to physiological and pathophysiological conditions.
Particularly, it is possible for skeletal muscle to selectively use fuel sources such as glycogen,
glucose and fatty acids for energy production depending on aerobic or anaerobic metabolism in
response to exercise or chronic contractile activity.7-9 Although skeletal muscle as a whole acts as
a contributor to glucose and fatty acid metabolism, the composition of fibers in individual muscle
plays a critical role in muscle energy metabolism. Specifically, the metabolic plasticity of fibers
in skeletal muscle relies on mitochondrial content and composition. Mitochondrial biogenesis—
which is generally referred to as mitochondrial adaptions responding to external stimuli such as
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exercise—increases mitochondrial volume and changes its composition, contributing to an
alteration of metabolic preference from glucose to fatty acids.10-12
Conjugated linoleic acid (CLA) is a mixture of geometric and positional conjugated
isomers of linoleic acid. The effects of CLA have been previously demonstrated to influence the
development of cancer and atherosclerosis, in addition to preventing osteoporosis and modulating
immune responses.13,14 Moreover, CLA has garnered special attention in the last two decades for
its anti-obesity effects through various mechanisms, such as the regulation of energy and lipid
metabolism, adipogenesis, inflammation and adipocyte apoptosis.15,16 Furthermore, in animal
models, it was reported that CLA improved voluntary activity and endurance capacity and
modulated energy metabolism.17,18
Although further studies are needed to demonstrate the role of CLA in skeletal muscle,
the accumulated evidence to date of increased lean body mass and improved physical activity
provide clues on how CLA might modulate skeletal muscle metabolism. Thus, we expect that the
regulating mechanisms of CLA in skeletal muscle can elucidate the preventive effects on obesity
along with currently known effects on adipose tissue. In addition, we expect that the information
obtained from the successful completion of this research will expand our understanding of the use
of bioactive food compounds and physical exercise to control obesity.

2

CHAPTER 2
LITERATURE REVIEW

2.1 Overview of CLA
Since the discovery of CLA in beef, it is known that the primary dietary sources of CLA
are meats and dairy products from ruminants. It is reported that in dairy products, CLA contents
range between 0.34 and 1.07% of the total fat, and in raw or processed beef range between 0.12
and 0.68%.19 Although we continuously consume CLA daily in foods originated from ruminant,
concentrations of CLA in food (less than 10 mg CLA/ g fat) are not substantial.20 The average
daily CLA intake in the U.S. from food sources is 104-151 mg and 176-212 mg for women and
men, respectively.21,22
CLA has two active isomers (cis-9,trans-11 and trans-10,cis-12 isomers), which produce
different biological effects.14 CLA isomers mostly originate from either biosynthesis or chemical
synthesis. The cis-9,trans-11 is a natural predominant isomer which accounts for over 80% of
CLA isomers and is derived from the biohydrogenation of rumen bacteria.23,24 In addition to cis9,trans-11, the most notable CLA isomer is the trans-10,cis-12. However, in natural foods the
amount of trans-10,cis-12 is very low. When chemical synthesis is used, this isomer forms in
significant amounts.20 Although CLA has at least 28 different isomers, cis-9,trans-11 and trans10,cis-12 isomers have demonstrated the most favorable health benefits. Currently, most
commercial CLA preparations are composed of almost equal amounts of cis-9,trans-11 and trans10,cis-12 isomers (also referred to as a CLA mixture or 50:50 mix).
Over the last two decades, studies have uncovered some negative health issues of trans
fat, and it is therefore necessary to define the trans fatty acids in CLA.25 The definition of trans
fat labeling by U.S. Food and Drug Administration (FDA) is “all unsaturated fatty acids that
contain one or more isolated double bonds in a trans configuration”.26 This definition means that
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conjugated linoleic acid (CLA) is ruled out from this regulation to label trans fats, since nonconjugated trans fatty acids are distinguished from conjugated forms. Further, in July 2008, the
FDA approved CLA for a GRAS (Generally Recognized as Safe) status for specific food
categories such as fluid milk, yogurt, meal-replacement shakes, nutritional bars, fruit juices and
soy milk. Thus, it is expected that there will be an increase in applications of CLA for human
health benefits.

2.2 CLA and Body Composition Change
The human body is typically composed of fat, muscle (protein or lean body mass), water
and bone, and measuring body composition is an efficient way to assess obesity. Most of the
initial CLA studies in animals used this method to determine CLA’s anti-obesity effects. Since
the first finding of the effect of CLA on body composition changes in mice in 1997,27 numerous
studies have reported that CLA supplementation contributed to modulate body composition by
reducing body fat and/or increasing lean body mass in various mammalian models.13-15,22,25
Herein, the previous studies in mice and rats on the changes in body composition including both
body fat mass and lean body mass are described in Tables 2.1 and 2.2. Among about 100 human
studies on body fat regulation, Table 2.3 summarizes the clinical trials measured changes of both
body fat reduction and lean body mass.

2.2.1 Effects of CLA on Body Fat Reduction
One of the most attractive aspects of CLA is to reduce body fat mass through various
mechanisms.15,16 According to the experimental purpose, previous studies have adopted different
strains, genders, forms and concentrations of CLA and varying durations in mouse studies (Table
2.1). The effect of CLA on body fat reduction is likely to be the most responsive in mice, where
previous studies at levels of 0.5-2.2% of dietary CLA mixture or 0.2% of single isomer have
shown a decrease in body fat mass by 40-80%.22 In the same context, 0.5-3.0% CLA-fed rats
4

Table 2.1. Effects of conjugated linoleic acid (CLA) on body composition in mice
Mouse

CLA Supplementation
Dosage
Duration
Formc
(%)d
Mixture
0.5
4 weeks

Resultse
BW

BFM

LBM

-

↓

↑

Food
Intake
↓

6 weeks

↓

↓

-

↓

0.25-1.0

6 weeks

↓

↓

↑

-

0.5

8 weeks

-

↓

↑

↓

0.5

4 weeks

↓

↑

↓

Mixture

1.0

5 weeks

-

↓

F

Mixture

1.0

5 months

-

↓

-

ICR

M

Mixture

0.1

4 weeks

-

↓

↑

Ohnuki et al., 200135

ddY

M

Mixture

0.25-1.0

4 and 8
weeks

↓

↓

-

Peters et al., 200136

PPARαKO

M

Mixture

0.5

4 weeks

↓

↓

↑

Park et al., 200137

ICR

F

Mixture

0.3

2 weeks

↓

-

-

Ntambi et al., 200238

ICR

F

Mixture

1.0

4 weeks

-

↓

↑

Hayman et al., 200239

BALB/c

M

Mixture

0.1-2.0

4 weeks

↓

↓

↑

Warren et al., 200340

C57BL/6N

F

c9t11/t10c12

0.5

8 weeks

↓

↓

-

ICR

F+M

c9t11/t10c12

1.0

6 weeks

-

↓

↑

Straina

Genderb

ICR

F+M

West et al., 199828

AKR/J

M

Mixture

1.0-1.2

DeLany et al.,
199929

AKR/J

M

Mixture

Park et al., 199930

ICR

F

Mixture

Park et al., 199931

ICR

F

West et al., 200032

AKR/J

M

C57BL/6J

Park et al., 200134

References
Park et al., 199727

Tsuboyama
200033

Chardigny
200341

et

et

al.,

al.,

Mixture /
c9t11/t10c12

↓ by
t10c12

-

Muscle Metabolism
Energy
Biomarkersg
Expendituref
↑ CPT
↑ EE / ↓ RQ

↑ EE
↓ TNF-α /
↑ GLUT4

↑ Oxygen
consumption
↑ CPT1 / ↑ UCP2
↓

↔EE/↔VA/↔RER
↔ Oxygen
consumption

(Continued)
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Table 2.1. Continued
Mouse
Straina

Genderb

BALB/c

M

CLA Supplementation
Dosage
Duration
Formc
(%)d
Mixture
0.5
6 weeks

MH/ML

M

Mixture

0.5

ICR

M

t10c12

Javadi et al., 200445

BALB/c

M

Ohashi et al., 200446

C57BL,
KK, KKAy

Javadi et al., 200447

References
Terpstra et al., 200342
Hargrave
200443

et

al.,

Park et al., 200444

Park et al., 200548
de Roos et al., 200549
Hargrave
200550

et

Resultse
BW

BFM

LBM

↓

↓

↑

Food
Intake
-

8 weeks

↓

↓

-

↓

0.5

3 weeks

-

↓

↑

Mixture

0.5

3 and 12
weeks

↓

↓

↑

F

Mixture

0.5

4 weeks

↓

↓

-

-

BALB/c

M

Mixture

4.0

5 weeks

-

↓

-

-

ICR

F

Mixture

0.5

4 weeks

-

↓

↑

↓

ApoE KO

M

c9t11/t10c12

2.1

12 weeks

↓

↓

-

-

M

Mixture

0.5

2 and 8
weeks

↓

↓

-

↓
-

al.,

Winzell et al., 200651

C57BL/6J

F

Mixture

1.0

12 weeks

↓

↓

↑

Bhattacharya et al.,
200652

BALB/c

M

Mixture

0.5

14 weeks

↓

↓

-

CD-1

F

t10c12

0.15/0.3

6 weeks

-

↓

-

ICR

F+M

Mixture

0.5

4 weeks

↓

↓

↑

↓

C57BL/6J

F

Mixture

0.5

8 weeks

↓

↓

-

-

BALB/c

M

Mixture

0.5

4 weeks

↓

↓

-

-

Viswanadha
200653

et

al.,

Park et al., 200754
Rahman et al., 200755
Javadi et al., 200756

Muscle Metabolism
Energy
Biomarkersg
Expendituref
↑ EE

↑ EE

↑ EE

↑ EE

(Continued)
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Table 2.1. Continued
Mouse
Straina

Genderb

ICR

M

CLA Supplementation
Dosage
Duration
Formc
(%)d
Mixture
0.5
4 weeks

N2KO

F

t10c12

Rahman et al., 200958

C57BL/6J

F

Andreoli et al., 200959

CF-1

M

Halade et al., 200960

C57BL/6J

F

Moon et al., 200961

ob/ob

M

Halade et al., 201062

C57BL/6J

F

Park et al., 201063

129Sv/J

F

Parra et al., 201064

C57BL/6J

M

Halade et al., 201165

C57BL/6J

F

Park et al., 201166

ICR

M

Fedor et al., 201367

C57BL/6N

F

CF-1

M

References
Park et al., 200715
Hur et al., 200957

Scalerandi
201468

et

al.,

Resultse
BW

↓

BFM

LBM

↓

↑

↓

-

Food
Intake

0.5

12 weeks

0.5

6 months

0.3

4 weeks

-

↓

-

0.5

6 months

↓

↓

↑

-

1.0

6 weeks

↓

↓

↑

-

0.5

6 months

↓

↓

↑

-

Mixture

0.5

4 weeks

↓

↓

↑

↓

Mixture

3/10
mg/day

5 weeks

↓

↓

-

-

Mixture /
c9t11/t10c12

0.5

6 months

↓

↓

↑

Mixture /
c9t11/t10c12

0.22/0.5

4 weeks

-

↓

↑

t10c12

0.5

4 weeks

↓

↓

-

Mixture

1.0

4 weeks

↓

↓

-

Mixture /
c9t11/t10c12
Mixture
Mixture /
c9t11/t10c12
Mixture
Mixture /
c9t11/t10c12

Muscle Metabolism
Energy
Biomarkersg
Expendituref

↑

↓ TNF-α / ↓ IL-6

↑ EE / ↓ RQ

↑ CPT-1 / ↑ UCP2
/ ↑ GLUT 4

-

-

a
ApoE KO, apolipoprotein E knockout; ddY, Deutschland, Denken, and Yoken; MH, metabolic rate high; ML, metabolic rate low; N2KO, Nescient helix-loop-helix 2 gene
knockout; PPARα-KO, peroxisome proliferator-activated receptor α knockout; SENCAR, sensitive to carcinogenesis.
b
F, female; M, male.
c
Mixture, a mixed isomer of cis-9,trans-11 and trans-10,cis-12; c9t11, cis-9,trans-11 CLA isomer; t10c12,trans-10,cis-12 CLA isomer.
d
Dosage (%) means a designated weight percentage of CLA in diet.
e
BW, body weight; BFM, Body fat mass; LBM, lean body mass; -, no change; ↑, increase; ↓, decrease.
f
EE, energy expenditure; RER, respiratory energy ratio; RQ, respiratory quotient; VA, voluntary activity.
g
CPT, carnitine palmitoyltransferase ; GLUT4, glucose transporter type 4; IL-6, interleukin 6; TNF-α, tumor necrosis factor alpha; UCP2, uncoupling protein 2; ↔, no change.
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Table 2.2. Effects of conjugated linoleic acid (CLA) on body composition in rats
Rat

Resultsd

Strain

Gendera

SD

M

CLA Supplementation
Dosage
Duration
Formb
(%)c
Mixture
3.0
7 weeks

SD

F

Mixture

0.25/0.5

1, 5 and 7
weeks

-

↓

-

Sisk et al., 200171

Zucker

M

Mixture

0.5

5 and 8
weeks

-

-

-

Kim et al., 200272

SD

M

Mixture

0.5-1.0

9 weeks

-

-

-

Yamasaki et al., 200373

SD

M

Mixture

1.5

3 weeks

-

↓

-

Henriksen et al., 200374

Zucker

F

Mixture /
c9t11/t10c12

0.42
g/day

3 weeks

↓ by
Mixture &
t10c12

↓ by
t10c12

-

Sanders et al., 200475

Zucker

F

Mixture /
c9t11/t10c12

0.42
g/day

3 weeks

-

-

Botelho et al., 200876

Wistar

M

Mixture

2.0

6 weeks

↓ by
Mixture &
t10c12
-

↓

↑

Ogborn et al., 200877

Han:
SPRD-cy

F+M

Mixture

1.0/2.0

12 weeks

-

↓

-

Roy et al., 200878

SD

M

Mixture

1.0

8 weeks

-

-

-

DeGuire et al., 201379

SD

F+M

Mixture

1.0

16 weeks

-

-

-

Wistar

M

Mixture

1.5

9 weeks

-

-

-

References
Stangl et al., 200069
Azain et al., 200070

de Almeida
201580

et

al.,

a

BW

BFM

LBM

↓

↓

↑

Food
Intake

-

↓ protein carbonyl /
↓ intramuscular TG /
↑ glucose uptake
by Mixture & t10c12

↑

F, female; M, male.
Mixture, a mixed isomer of cis-9,trans-11 and trans-10,cis-12; c9t11, cis-9,trans-11 CLA isomer; t10c12,trans-10,cis-12 CLA isomer.
c
Dosage (%) means a designated a designated weight percentage of CLA in diet.
d
BW, body weight; BFM, Body fat mass; LBM, lean body mass; -, no change; ↑, increase; ↓, decrease.
e
TG, triglyceride.

b
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Muscle Metabolism
Energy
Biomarkerse
Expenditure

Table 2.3. Effects of conjugated linoleic acid (CLA) on body composition in humans
Subject
Characteristic

Gendera

Overweight /
Obese

F+M

CLA Supplementation
Dose
b
Duration
Form
(g/day)
Mixture
3.4
12 weeks

Blankson et al.,
200082

Overweight /
Obese

F+M

Mixture

1.7/3.5/
5.1/6.8

Zambell et al.,
200083

Normal

F

Mixture

Kreider et al.,
200284

Normal /
Overweight

M

Riserus et al.,
200285

Obese

Kamphuis et al.,
200386
Gaullier
200487

Resultsc
Energy
Expenditured

BW

BFM

LBM

↓

-

-

6 and 12
weeks

-

↓ 1.7, 3.4 and
6.8 at 12 wk

↑ 6.8 at
12 wk

2.5

9 weeks

-

-

-

Mixture

6.0

4 weeks

-

-

-

M

Mixture /
t10c12

3.4

12 weeks

↓ by t10c12

↓ by Mixture
and t10c12

-

Overweight

F+M

Mixture

1.8/3.6

13 weeks

-

↓

↑

↑ RMR

al.,

Overweight

F+M

Mixture
(TG/Free
form)

3.6/3.4

1 year

↓

↓

↑

↑ EE

MalpuechBurugere et al.,
200488
Riserus et al.,
200489

Overweight

F+M

TG of c9t11
and t10c12

1.5/3.0

18 weeks

-

-

-

Obese

M

TG of c9t11

3.0

12 weeks

↑

-

-

Gaullier
200590

Overweight

F+M

Mixture
(TG/Free
form)

3.6/3.4

2 year

↓

↓

-

Normal

F

Mixture

3.6

6 weeks

↓

↓

↑

Overweight /
Obese

F+M

Mixture

3.4

1 year

-

-

-

References
Berven et
200081

et

et

al.,

al.,

Colakoglu et al.,
200691
Larsen
200692

et

al.,

Other comments

↔ RMR /↔ REM

Subjects with
metabolic
syndrome
Weight regain

Free form
increased LBM /
↓ food intake
↓ Food intake

1 year extension
open study /
↓ food intake

Weight regain /
hypocaloric diet

(Continued)
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Table 2.3. Continued
Subject
References
Pinkoski et
200693

Resultsc

CLA Supplementation

Characteristic

Gendera

Formb

Dose (g/day)

Duration

al.,

Unknown

F+M

Mixture

5.0

7 weeks

BW

BFM

LBM

↓

↑

Gaullier
200794

et

al.,

Overweight /
Obese

F+M

Mixture

3.4

6 months

-

↓

↑

Lambert
200795

et

al.,

Normal /
Overweight

F+M

Mixture

2.6

12 weeks

-

-

-

Laso et al., 200796

Overweight /
Obese

F+M

Mixture

3.0

12 weeks

-

↓

-

Nazare et al.,
200797

Normal /
Overweight

F+M

Mixture
(TG)

2.8

14 weeks

-

-

Obese

F+M

Mixture

3.2/6.4

12 weeks

-

Tarnopolsky et
al., 200799

Normal /
Overweight

F+M

Mixture

5.4 + 5 g
creatine
monohydrate

6 months

Watras et al.,
2007100

Overweight

F+M

Mixture

3.2

Steck et al.,
200798

Energy
Expenditured
↔ RMR

Other comments
↓ Protein
degradation
↔ Calorie intake

↔ RMR

↔ Appetite

-

↑ RMR

↓ Food intake

-

↑

↔ RMR /↔ RQ

-

↓

↑

6 months

↓

↓

-

Cosupplementation/
aging study model
↑ RMR

↔ Energy intake

Diaz
et
2008101

al.,

Overweight /
Obese

F

Mixture

1.8 + 0.4 mg
creatine
picolinate

12 weeks

-

-

-

Cosupplementation/
Premenopausal

Park
et
2008102

al.,

Overweight /
Obese

F+M

Mixture

2.4

8 weeks

↓

-

-

↓ Food intake

al.,

Normal /
Obese

M

Mixture

2.3 + 1.3 g
ω-3 fatty acid

12 weeks

↑

-

↑

Cosupplementation/
Crossover design

al.,

Obese

F

Mixture

6.4

16 weeks

↓

↓

-

Type 2 diabetes /
postmenopausal

al.,

Normal /
Overweight /
Obese

F

Mixture /
c9t11

5.5/4.7

16 weeks

-

↓ by
Mixture

↑ by
Mixture

Postmenopausal

Sneddon
2008103
Norris
2009104

et
et

Raff
et
2009105

(Continued)
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Table 2.3. Continued
Subject

Resultsc

CLA Supplementation

Energy
Expenditured

Characteristic

Gendera

Formb

Dose (g/day)

Duration

BW

BFM

LBM

al.,

Obese

F+M

Mixture

4.3 + 9 g
creatine
monohydrate
+ 36 g whey
protein

5 weeks

-

-

↑

↔ Energy intake

al.,

Overweight /
Obese

F+M

Mixture
(TG)

2.4

7 months

↓

↓

↑

Childhood model

Joseph et al.,
2011108

Overweight /
Obese

M

Mixture /
c9t11

2.8/2.7

8 weeks

-

-

-

Crossover design

Chen et al.,
2012109

Overweight /
Obese

F+M

Mixture

1.7

12 weeks

↓

↓

-

Macaluso et al.,
2012110

Normal /
Overweight

M

Mixture

4.8

3 weeks

-

-

-

Lopez-Plaza et al.,
2013111

Overweight

F+M

Mixture

3.0

24 weeks

↓

↓

-

Shadman et al.,
2013112

Overweight

F+M

Mixture

2.4 + 100
IU/day
Vitamine E

8 weeks

-

-

-

Cosupplementation/
Type 2 diabetes

Ormsbee et al.,
2014113

Overweight /
Obese

F+M

Mixture

CLA +
Green tea +
BCAA
(branched
chain amino
acid)

8 weeks

↓

-

-

Cosupplementation

References
Cornish et
2009106

Racine
2010107

et

a

Other comments

Crossover design /
serum testosterone ↑

F, female; M, male.
Mixture, a mixed isomer of cis-9,trans-11 and trans-10,cis-12; c9t11, cis-9,trans-11 CLA isomer; t10c12,trans-10,cis-12 CLA isomer; TG, triglyceride form; Free form, free
fatty acid form.
c
BW, body weight; BFM, Body fat mass; LBM, lean body mass; -, no change; ↑, increase; ↓, decrease.
d
EE, energy expenditure; RER, respiratory energy ratio; RMR, resting metabolic rate; RQ, respiratory quotient; ↔, no change.

b
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accumulated less body fat, although the magnitude of the reduced body fat was dependent on the
strain of rats and the site of the adipose tissue (Table 2.2). Specifically, CLA supplementation in
Sprague-Dawley rats showed the reduced peritoneal and parametrial fat mass by 25-30%.70
Additionally, 0.5% CLA diets in OLETF rats induced 14% and 44% less fat accumulation in
omental and epididymal adipose tissues, respectively.114 Along with the availability of purified or
enriched CLA isomer, further studies have demonstrated the specific CLA isomers’ effects on
body fat accretion. With respect to body fat reduction, the trans-10,cis-12 CLA isomer was
identified as the primary active form in mice, not the cis-9,trans-11 isomer.18,31,58,62,115 In
congruence with the mice study, the trans-10,cis-12 CLA isomer remarkably induced a reduction
of body weight and fat mass in OLETF rats.116 Also, 1.5% CLA mixture fed Zucker diabetic fatty
(ZDF) rats had significantly lower body weight gain and fat mass, while it was observed that the
cis-9,trans-11-fed group had no effect on changes in body composition, especially body fat
reduction.117 In another isomer-specific study, the eight week feeding trans-10,cis-12 isomer did
not achieve significant changes in body weight and adipose mass in the same rat strain.118
On the basis of evident results from animal studies, a number of clinical trials have been
carried out to determine the effects of CLA on body fat accretion.14,22,119 Human intervention
studies of supplemented CLA mostly used the CLA mixture form (cis-9,trans-11 and trans10,cis-12 isomers). Although accumulating evidence elicits the effect of CLA on the reduction of
body fat mass in humans,120 it is less responsive to animal studies, especially compared to the
mouse model.
In addition, the subjects’ weight status may contribute to CLA’s efficacy on body fat
control. Normal weight subjects supplemented with 0.7-5.5 g of CLA mixture for 4-16 weeks had
a decreased body fat mass by 4-20%,91,93,105,121-123 whereas overweight and obese individuals
treated with 1.7-6.8 g of CLA mixture for 4-104 weeks showed reductions of 315%.81,85,88,89,98,108,124-127 However, other studies observed no effect of CLA on body fat mass in
both subject groups (normal and overweight/obese).22 Interestingly, the study in 6-10 year old
12

overweight and obese children at levels of 3 g of CLA mixture for 7 months significantly reduced
peripheral and abdominal body fat accumulation (%).107 Moreover, Ha et al.128 reported that 15year-old obese volunteers supplemented with 6 g of CLA mixture for 6 months had decreased
body weight and fat content, as well as improved physical activity. To date, there are two metaanalyses focused on both body weight and body fat mass to establish a significant dose and
duration for CLA’s efficacy.129,130 Whigham et al.129 reported that 3.2 g/day CLA supplementation
led to significantly reduce body fat mass in humans, although it was a modest loss. A study by
Blankson et al.82 supported this finding, demonstrating that CLA’s effective dose of body fat
reduction plateaued at 3.4 g/day between the range of 1.7 and 6.8 g/day. Along with CLA’s dose
efficacy, they reported that supplementation with CLA up to 6 months linearly reduced body fat,
then attenuated response and eventually showed no additional effect at approximately 2 years.
This is consistent with a meta-analysis in overweight and obese individuals based on fifteen
previous clinical trials,130 indicating long-term CLA intake significantly induces loss in body
weight and fat mass.
Combining all these results together, CLA likely reduces body fat mass. However, it is
not mirrored in body weight decrease, since CLA might be involved in other composition
changes in the body. In fact, the previous clinical studies showed no changes in body weight by
CLA supplementation even though body fat reduction occurred.82,86,94,96,99,105,113 In support of
these observations, body fat mass and lean body mass were simultaneously influenced by CLA
supplementation. Particularly, seven human intervention studies 82,87,91,93,94,99,105 along with eight
publications in rodents27,29-31,54,62,63,69 demonstrated reduced body fat accretion as well as increased
lean body mass by CLA supplementation. Thus, it is important to further investigate the effects of
CLA on lean body mass.

2.2.2 Effects of CLA on Increased Lean Body Mass
In terms of the effects of CLA on body composition change, most studies have been
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focused on the decreased body fat mass. However, a growing body of evidence elucidates the
importance of increased lean body mass, body proteins (%), or specific skeletal muscle tissue
(gastrocnemius and quadriceps muscle) weights on anti-obesity effects of CLA, as lean body
mass is highly associated with energy expenditure.14-16,120
To elicit CLA’s effects on the change of lean body mass, various studies either including
or excluding exercise regimens in animals and humans were conducted (Table 2.1, 2.2 and 2.3).
Along with reduced body fat mass, 0.25-0.5% CLA mixture supplementation significantly
increased body protein (%) in body composition in mice.27,29,30,54,63,131,132 The trans-10,cis-12 CLA
isomer significantly increased protein accretion in various mouse models.18,31,58,62 These results
suggest that the trans-10,cis-12 CLA isomer plays a critical role in body composition changes,
since in most CLA supplementation studies on body fat reduction as well as increased lean body
mass, the effect of the cis-9,trans-11 CLA isomer was not observed. Interestingly, in over 12month-old C57BL/6J, 0.5% of the trans-10,cis-12 isomers and CLA mixture for a 6 month
intervention showed prevention of age-associated skeletal muscle loss without a training
regimen.58,60 In Sprague-Dawley rats, 3.0% CLA mixture supplementation increased lean body
mass.69 This change was also shown with 0.5-1.0% CLA treatment in Wistar rats for 6-10
weeks.133,134 It was suggested that CLA supplementation caused repartitioning of body
composition, less adipose depots and more lean mass.69 There are consistent reports that CLA
contributes to increased lean mass in different cross-bred pigs. The CLA mixture between 0.25
and 2% acted as a repartitioning agent to induce decreased back fat and increased lean body mass
in pigs.135-139
The intervention study of CLA in humans yielded less substantial and partially contrary
results compared to those observed in the animal models (Table 2.3). In fact, the results in human
studies varied with regard to the changes in body weight, body fat mass and lean body mass
(Table 2.4). In terms of the prevention of obesity, group I and II in Table 2.4 are the ideal
outcomes after CLA supplementation. While increased lean body mass may group a perceived
14

body weight gain like group II and/or III, this change in body composition would also provide
additional health benefits beyond simply a decreased value in body weight.
Among clinical trials with CLA supplementation independent of exercise training, five
of them reported that the body composition change of not only reduced body fat but also of
increased lean body mass.86,87,94,105,107 Specifically, the duration of supplementation with CLA in
these studies were 3-12 months, indicating the long-term intervention might be more helpful to
increase lean body mass even without exercise. Moreover, two studies with no exercise regimen
reported that supplemented CLA showed no body fat reduction but showed an increase of lean
body mass.98,103 Schoeller et al.140 demonstrated the overall effects of CLA on lean body mass
using a meta-analysis in 18 independent clinical studies. These studies made the conclusion that
CLA supplementation led to a relatively rapid onset of increased lean body mass, however the
total increase was not drastic (less than 1%). This result supports the previous mouse study,30
implying CLA affects body composition through modulating lean muscle mass, prior to reducing
fat mass. It suggests that CLA may target muscle metabolism to reduce body fat through
metabolic alteration in skeletal muscle.

Table 2.4. The grouping dependent on the changes in body weight (BW), body fat mass (BFM)
and lean body mass (LBM) after CLA supplementation in human studies
Group

BW

BFM

LBM

References

I

↓

↓

↑

87,91,107

II

-

↓

↑

82,86,93,94,99,105

III

↑

-

↑

103

IV

↓

↓

-

85,90,100,104,109,111

V

-

-

-

83,84,88,92,95,97,101,108,110,112,141
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2.2.3 Mechanism of Body Composition Change by CLA
The source of energy intake is simply from consumed food, while source of energy
expenditure comes from several forms such as basal metabolic rate (BMR), adaptive
thermogenesis and physical activity. The regulation of body composition is relevant to energy
balance, since energy intake over energy expenditure leads to the storage of excess energy as fat
in the body. Multiple mechanisms to better understand the CLA effects on body composition
change have been demonstrated.15,16,142 These approaches are mostly associated with CLAmediated energy modulation including lowered energy intake and enhanced energy expenditure
along with the inhibition of fat accumulation in adipose tissue.

2.2.3.1 Regulation of Energy Balance by CLA
On the basis of previous observations demonstrating energy balance changes by CLA
supplementation in animals and humans, the putative mechanisms of CLA on the regulation of
energy balance are the reduction of food intake and the increase of energy expenditure.
Early studies demonstrated CLA-fed mice showed a reduced food intake as a function of
body fat reduction, whereas others have reported inconsistent results in comparison with the
former (Table 2.1). Similarly, this discrepancy on food intake was reported in rat studies. In fact,
two studies of CLA supplementation independent to exercise regimens reported decreased food
intake in rats,117,143 while others observed no change in food intake by CLA.133,144-146 In theory,
reduced food intake causes fewer gains of body weight and body fat, which may affect overall
body composition changes. Herein, it is questionable whether body fat reduction by CLA is
derived from decreased food intake or other causes. With regard to this question, the subsequent
study clearly answered that CLA’s effects on body composition change were independent of
lowered food intake by using a pair feeding comparison.54 This conclusion supports human
clinical trials, since they did not support the correlation between CLA supplementation and
reduced food intake.87,88,90,94,100,106,147 Thus, it is unlikely that food intake reduction by CLA is a
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main function of body composition change.
Next, we should consider energy expenditure, as enhanced energy expenditure is a
primary function that influences body composition, including body fat reduction. CLA
supplementation has provided various pieces of evidence to show enhanced energy expenditure
with increased oxygen consumption in animal models.17,28,32,35,63,116,131,133,148,149 In clinical trials
CLA supplementation increased BMR (same as resting metabolic rate, RMR),86,97,100,150 whereas
other studies did not report an influence of CLA on BMR regardless of changes to body
composition.83,93,95,98 Thus, further human studies are needed to provide a more clear
interpretation of the effect of CLA on basal metabolic rate.
CLA supplementation is likely involved in the activation of thermogenesis, as early
studies demonstrated CLA upregulates uncoupling proteins (UCPs) expressed in various tissues
such as adipose, liver and skeletal muscle in mice and rats.17,33,63,117,144,151,152 Adaptive
thermogenesis is responsible in mitochondria-mediated biochemical processes, especially in
combusting stored or excess energy into heat, where UCPs play a crucial role. UCP1 to UCP5 are
expressed in distinct tissues in body, although their basic role to generate heat by using ATP is
almost same.153
Along with the internal heat produced by BMR and thermogenesis, physical activity by
contractile skeletal muscle works to expend energy, thus contributing to body fat reduction.
Although the magnitude of energy expended in physical activity varies depending on the type
(resistance or endurance training), intensity, duration and frequency of exercise, CLA
supplementation may affect physical activity and subsequently regulate energy expenditure. In
fact, previous studies in rodents reported that a combination of CLA supplementation with
endurance training enhanced energy consumption,131,133,149 while the results of clinical studies
were inconsistent.93,97,154
At the cellular level, energy expenditure may be explained by biochemical events. To
convert stored or excess fat in the body into energy, fatty acid β-oxidation plays a pivotal role,
17

resulting in reduced body fat mass and subsequently leads to even or negative energy balance.
Although increased fat oxidation in the CLA-fed animals might be estimated by the alteration of
energy sources based on measurements of the respiratory quotient (RQ, the representative marker
for assessment of a primary energy source either carbohydrate or fat),28,35,116,131,133,148,149 the
upregulation of carnitine palitoyltransferase 1(CPT-1) in skeletal muscle as the direct marker for
fatty acid β-oxidation provided more reliable evidence of enhanced lipid
metabolism.17,18,27,36,63,145,155-158 Intriguingly, Close et al.150 reported supplemented groups with 4 g
of CLA mixture for 6 months had significantly increased fat oxidation and energy expenditure
during sleep in human subjects.
Herein, we discussed the effects of CLA on the regulation of energy balance by food
intake and energy expenditure, suggesting CLA might lead to the negative energy balance
(energy intake less than consumption) in the whole body. Thus, we need to look into the tissuespecific functions of CLA.

2.2.3.2 Effect of CLA on Adipocyte Metabolism
Adipose tissue undergoes two physiological and morphological events to grow:
hyperplasia (increase in cell number) and hypertrophy (increase in cell size). While hyperplasia
plays a critical role in proliferation of preadipocytes involved in adipogenesis, hypertrophy is
responsible for the continuous storage of excess energy in adipose tissue, directly leading to
adiposity.159 The mechanisms of CLA on adipocytes are elucidated to in in vitro and in vivo
experimental models.15,16,119 The suggested mechanisms to date are (1) suppression of lipogenesis;
(2) stimulation of lipolysis; (3) inhibition of adipogenesis; and (4) modulation of cytokines /
adipokines. The trans-10, cis-12 CLA isomer, not the cis-9, trans-11 CLA isomer, is the active
form in these mechanisms. Of particular importance, CLA mostly interacts with peroxisome
proliferator-activated receptor γ (PPARγ), which is a key regulator of lipogenesis, lipolysis,
adipogenesis and inflammation in adipocyte metabolism.160,161
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First, the putative mechanism to reduce body fat by CLA is the suppression of
lipogenesis, since several studies reported that CLA supplementation attenuated the expression
levels of stearoyl-CoA desaturase (SCD), acetyl-CoA carboxylase (ACC), fatty acid synthase
(FAS) and sterol regulatory element-binding protein-1 (SREBP1).33,162-165 Second, CLA
stimulates lipolysis via the activation of hormone sensitive lipase (HSL), inducing the
mobilization of stored triglyceride and the subsequent release of free fatty acid and glycerol
cleavage.161 However, there is still a debate regarding the effects of CLA on lipolysis.166-16827,31,167169

Third, CLA inhibits adipogenesis through reduced PPARγ expression levels. The key

transcription factors to induce adipogenesis are PPARγ and CAAT/enhancer binding proteins
(C/EBPs). For differentiation from preadipocytes to adipocytes, C/EBPβ and C/EBPδ are
primarily increased, activating the transcription of C/EBPα and PPARγ. Particularly, the trans10,cis-12 CLA isomer suppressed the activity of PPARγ and C/EBPs as well as related target
genes such as acyl-CoA binding protein (ACBP) and perilipin on adipogenesis.163,164,170-173163,170,174
Last, CLA may modulate cytokines such as nuclear factor kappa-light-chain-enhancer of
activated B cells (NFκB) through IκB and IκB kinase (IKK), subsequently inducing an increase
of tumor necrosis factor α (TNFα), interleukin (IL) 6 and 8 and IL-1β, associated with
inflammatory mechanisms. In addition, CLA may induce adipokines like leptine and adiponectin,
representing the total amount of adipose tissue, resulting in a decrease of TG synthesis and an
increase of lipolysis.171-173,175,176
Collectively, CLA may have the potential to regulate body composition change,
although the magnitude of efficiency is dependent upon several variables. While the effects of
CLA on adipocyte metabolism are supported by strong evidence, the role of CLA on skeletal
muscle metabolism and its main organization of energy expenditure is not fully known. However,
the previous studies showed that increased lean body mass and enhanced thermogenesis and fatty
acid β-oxidation in muscle with CLA might be associated with skeletal muscle metabolism.
Particularly, the interaction of CLA with exercise might be able to provide critical evidence of
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CLA’s effects on metabolism in skeletal muscle.

2.3 CLA and Skeletal Muscle Metabolism
The potential effects of CLA on skeletal muscle metabolism have drawn relatively less
interest, even though CLA also plays a central role in the regulation of energy balance in the
body. Skeletal muscle typically accounts for nearly 40 % of the total body mass and acts as a
significant regulator in overall energy metabolism.177 Generally, muscle metabolism is a term
used to describe the complex biochemical reactions associated with the function and development
in muscle. These reactions modulate energy metabolism in muscle, thereby influencing energy
expenditure by the alteration of exercise ability and adaptive thermogenesis. The discovery of
increased lean body mass and upregulated molecular markers predominately expressed in skeletal
muscle, such as CPT1 and UCP2 and 3, by CLA supplementation in the previous studies provide
the opportunity to uncover the correlation between CLA intake and muscle metabolism.

2.3.1 Energy Metabolism in Skeletal Muscle
In general, energy is derived from glucose and fatty acids in skeletal muscle. In the
muscle fibers, glucose and fatty acids are stored as modified structures, glycogen and
triglycerides, respectively. Although energy substrates used by muscle depend on the type,
intensity and duration of muscle work of the subject, skeletal muscle predominantly prefers to use
energy sources from fatty acids at rest. On the other hand, during high-intensity performance,
anaerobic metabolic pathways such as anaerobic glycolysis and the creatine kinase reaction
provide energy as primary sources when aerobic metabolism alone is not possible to cope with
energy demands in exercising muscle fibers.7-9 Low-intensity endurance exercise corresponding
to less than 60% of maximal oxygen uptake, like jogging and swimming, consumes glucose and
fatty acids as the primary energy sources during the first hour. Subsequently, prolonged
endurance exercise during the following one to four hours causes the substantial uptake of free
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fatty acids from intramuscular fat and stored triglycerides in adipose tissue as an energy source in
skeletal muscle.178 Thus, prolonged endurance exercise is the better way to use up stored fat in the
body through enhanced aerobic metabolism.
Skeletal muscle integrates a number of biochemical processes for energy homeostasis
between demand and supply. Cells in skeletal muscle store chemical energy as adenosine
triphosphate (ATP) and phosphocreatine, which are immediate sources of energy. In terms of
energy metabolism, skeletal muscle continuously produces energy derived from the hydrolysis of
ATP in response to energy demand by skeletal muscle contraction and relaxation. During skeletal
muscle work, ATPases break down ATPs and release 7.3 kcal per ATP of energy. This process is
divided into anaerobic (absence of oxygen) and aerobic (presence of oxygen) metabolic
pathways.178
Glycolysis is the catabolic pathway for glucose in the cytosol under both anaerobic and
aerobic conditions. In skeletal muscle, anaerobic glycolysis (breakdown of glycogen) permits
energy supply under certain circumstances like high-intensity muscular performance when
aerobic metabolism alone cannot provide sufficient levels of ATP. However, its net yield is only
2 ATP by the oxidation of 1 mole of glucose. In addition to anaerobic glycolysis, the degradation
of phosphocreatine by creatine kinase is another metabolic pathway that generates ATP under
anaerobic conditions in skeletal muscle.
Aerobic metabolism, especially aerobic glycolysis, in skeletal muscle takes place in the
mitochondria, which is an efficient way to produce ATP through mitochondrial oxidative
phosphorylation. Subsequently, a total of 38 ATP are produced from 1 mole of glucose under
aerobic conditions. Along with oxidative phosphorylation in mitochondria, the citric acid cycle
(Krebs or tricarboxylic acid (TCA) cycle) plays a critical role in energy generation in aerobic
metabolism. In fact, the process of ATP production is tightly regulated among cytosolic
glycolysis, mitochondrial β-oxidation and the citric acid cycle in skeletal muscle.179
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2.3.2 Intracellular Signaling Pathways Regulating Muscle Metabolism
Skeletal muscle is a tissue to show metabolic plasticity in response to alterations of
external and internal conditions such as nutrient deprivation during fasting or calorie restriction
and contractile activity including exercise.180 Upon a decrease of nutrient availability, muscle
switches its mode from glucose to fatty acid utilization as a main energy substrate.181 In response
to endurance exercise, skeletal muscle triggers a remodeling fiber-type from oxidative slowtwitch to glycolytic fast-twitch fibers.11 These adaptations in skeletal muscle are accompanied by
an increase in mitochondrial biogenesis, which are phenotypic alterations: increased volume
(content per gram of tissue) and changed composition (protein-to-lipid ratio in inner
mitochondrial membrane) in mitochondria.10 Moreover, metabolic reactions including aerobic
glycolysis, fatty acid β-oxidation, TCA cycle and oxidative phosphorylation rely on
mitochondria, as these metabolic events take place in mitochondria, suggesting that enhanced
mitochondrial biogenesis contributes to increased energy expenditure.182 The purpose of these
metabolic alterations is to enhance energy production. Consequently, in order to properly regulate
energy homeostasis, these adaptations positively regulate various molecular biomarkers involved
in energy metabolism in skeletal muscle.180
A number of regulators participate in these adaptive responses in skeletal muscle, among
them AMP-activated protein kinase (AMPK) is the prime initial sensor of fuel and energy status
in skeletal muscle.183 Particularly, AMPK controls a regulatory pathway in fatty acid β-oxidation.
AMPK negatively activates acetyl-CoA carboxylase (ACC), inducing the inhibition of malonylCoA, which is the suppressor of CPT1 (a rate-limiting enzyme for fatty acids β-oxidation in
mitochondria). As a consequence of reduced susceptibility to this shuttling system, fatty acid βoxidation is increased. Similar to AMPK, sirtuin 1 (SIRT1, a conserved nicotinamide adenine
dinucleotide (NAD)+-dependent deacetylase) acts as a sensor in response to the metabolic stimuli
such as stress, starvation or calorie restriction. SIRT1 regulates several transcriptional factors
such as protein 53 (p53), forkhead box O (FOXO) and NFκB. SIRT1 has drawn special attention
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to the factor working for longevity.184 Indeed, AMPK and SIRT1 may coherently mediate the
response at the cellular level to stress and the reduced nutrient availability in skeletal muscle.185
Peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α), a downstream
marker regulated by AMPK and SIRT1, is an inducible coactivator and a master regulator for
mitochondrial biogenesis, which orchestrates several transcription factors such as PPARs, nuclear
respiratory factor (NRF) 1 and 2, estrogen-related receptor α (ERRα) and myocyte enhancer
factor 2 (MEF2), to initiate mitochondrial biogenesis and induce the change in fiber
characteristics in skeletal muscle.186,187
Skeletal muscle is classified into three different fiber types in humans and four different
fiber types in rodents that have different physiological and metabolic characteristics. Typically,
skeletal muscle fibers are divided into two subcategories, slow-twitch and fast-twitch, and are
correlated with contractile properties.188 The fiber in human is composed of three myosin heavy
chain (MHC) isoforms: MHC I, MHC IIa, and MHC IIx/d. MHC I is slow twitch type I fibers,
which has a greater mitochondrial content, oxidative capacity and resistance to fatigue by using
fatty acids as a main energy source; compared to MHC IIx/d, a fast twitch type II fiber as known
glycolytic fiber that uses glucose and phosphocreatine as a primary energy provider; the
peculiarity of MHC IIa is intermediate between MHC I and IIx/d.189
The first genes to be implicated as a fiber type transformation are PGC-1α and PPARδ.
In transgenic mice, ectopically expressing PGC-1α in skeletal muscle induces muscle fiber
conversion of fast-twitch type II fibers into slow-twitch type I fibers.190 In a similar manner, the
overexpression of PPARδ (the most abundant form of PPARs in skeletal muscle) interacts with
PGC-1α and is highly involved in the development of mitochondrial oxidative type I fibers in
skeletal muscle.191,192 Taken together, a signaling cascade from AMPK to PPARδ is a relevant
metabolic pathway to regulate metabolism in skeletal muscle. Thus, we primarily target this
pathway to decipher the mechanism of CLA on skeletal muscle metabolism.
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2.3.3 Effects of CLA on Skeletal Muscle Metabolism
It has been revealed that long-chain fatty acids (LCFAs) with over 14 carbons, including
CLA, are primary endogenous ligands of the nuclear receptor family of transcription factors
PPARs (PPARα, γ and δ). Indeed, it is known that LCFAs regulate energy metabolism in skeletal
muscle.193
With regard to the regulation of skeletal muscle metabolism, the previous studies
reported the effects of CLA isomers and mixture on AMPK expression levels in murine skeletal
muscle cells. Both the cis-9,trans-11 and trans-10,cis-12 isomers stimulated the phosphorylation
of AMPK (active form), resulting in improved muscle energy metabolism.194-196 In addition, each
CLA isomer positively regulates ACC expression levels, indicating CLA treatment may affect
enhanced fatty acid β-oxidation.194,196 The cis-9,trans-11 CLA isomer showed elevated AMPK
phosphorylation with lower concentrations (~50 µM), while the trans-10,cis-12 isomer gradually
activated phosphorylated AMPK up to 120 µM in a dose-dependent manner, and then
plateaued.195 Compared to several studies of CLA on AMPK, it is limited on the effect of CLA on
SIRT1 activity in skeletal muscle, even though AMPK and SIRT1 both mutually regulate and
share many common target molecules.185
Although sufficient evidence demonstrating the role of CLA in mitochondria in skeletal
muscle has not yet been provided, recent studies reported direct and/or indirect effects of CLA on
the biochemical alteration of several molecular markers associated with mitochondrial biogenesis
and metabolism.18,58,152,197-199 In fact, CLA treatment in human skeletal muscle cells did not affect
the activity of PGC-1α, a primary regulator in mitochondrial biogenesis, even when
mitochondrial content was increased by CLA.197 In a similar context, CLA fed mice and rats
demonstrated no significant differences in PGC-1α compared to controls.152,198 On the other hand,
CLA supplementation significantly upregulated molecular biomarkers such as succinate
dehydrogenase, cytochrome c oxidase, superoxide dismutase 2, catalase and glutathione
peroxidase in skeletal muscle, resulting in increased ATP production and thermogenesis via
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improved oxidative phosphorylation and anti-oxidative capacity in rodent models.58,152
In regards to the effect of CLA on PPARδ, one of key regulators in muscle fiber type
transformation, 50 µM of CLA mixture added to murine muscle cells showed a significant
increase in PPARδ expression levels.199 Supporting this result, Kim et al.18 reported the trans10,cis-12 CLA isomer supplementation significantly upregulated PPARδ gene expression level in
mouse skeletal muscle, while Parra et al.198 observed no CLA effect on PPARδ and muscle fiber
change in mice. Although further investigation is required in in vivo studies for a better
understanding on the correlation between CLA supplementation and muscle fiber type switch,
CLA fed pigs showed a remarkably altered gene expression of muscle fiber types.200,201 In these
studies, 1.2-2.0% of CLA supplementation significantly increased the expression levels of
oxidative type I fiber, but not the expression levels of glycolytic type IIb and IIx fibers in skeletal
muscle.

2.3.4 Effect of CLA on Physical Activity
On the basis of the effects of CLA on increased muscle mass relative to fat mass gains, a
number of studies in animals and humans were carried out to evaluate the interaction of CLA
supplementation with exercise (Table 2.5 and 2.6). Exercise is typically divided into two distinct
trainings, resistance and endurance, relying on the metabolic system to produce ATP by
anaerobic and aerobic conditions, respectively. The previous animal studies of supplemented
CLA along with exercise provided a better understanding of improved endurance capacity via
mitochondrial fatty acid β-oxidation than resistance capacity (Table 2.5). In fact, 0.5-1.0% CLA
supplementation combined with endurance training showed a significantly greater fat oxidation in
skeletal muscle, resulting in an increased maximum swimming or running capacity in mice.149,202204

Specifically, Kim et al.18 reported that the trans-10,cis-12 isomer increased the maximum

running time and distance significantly over the cis-9,trans-11 treated animals in the trainedmice. Interestingly, the effect of CLA on physical activity is also supported by animal studies that
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measured voluntary activity (non-exercise physical activity), showing increased voluntary
movement along with the upregulation of CPT1 and UCP2.17,205 In rat models, no synergistic
effects of CLA treatment and exercise training on endurance capacity and lean body mass were
observed.133,134
Currently, there have been seventeen CLA intervention studies reported in humans
associated with exercise (Table 2.6). Among them, ten studies have tested exercise outcomes.
Overall, the outcomes in physical activity of CLA supplementation dependent on exercise were
inconsistent. Five clinical trials demonstrated the positive results of combined CLA with a
resistance-training regimen.82,93,99,106,110 Only Colakoglu et al.91 reported a synergistic effect of
CLA with endurance training. Furthermore, there were four clinical trials that evaluated the effect
of CLA supplementation without exercise on physical activity.94,100,128,206 Among them, two
studies showed improved physical activity by CLA treatment for 3 or 6 months.100,128
Four studies in humans evaluated the effects of cosupplementation of CLA with other
supplements such as creatine monohydrate, chromium picolinate, whey protein or amino acids
under physical training.99,101,106,207 Two cosupplementation studies of CLA and creatine
monohydrate for short- (5 weeks) or long-term (6 months) interventions, accompanied with
resistance training, showed increased lean body mass and improved strength compared to the
control.99,106 Interestingly, Macaluso et al.110 carried out a clinical trial to investigate the effect of
CLA with resistance training on testosterone levels in serum. This study designed a short-term
intervention (3 weeks), showing no change of body weight, fat mass and lean body mass.
However, serum testosterone levels were significantly increased by CLA supplementation and
resistance exercise. Subsequently, Barone et al.204 demonstrated that CLA supplementation
promoted endurance capacity in mice trained on the rotarod via the upregulation of testosterone
biosynthesis. Recently, Usui et al.208 suggested that enhanced mitochondrial biogenesis in skeletal
muscle led to the testosterone-induced increase in energy expenditure. This may provide another
clue to help explain how CLA can enhance energy expenditure and improve physical activity via
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Table 2.5. Effects of conjugated linoleic acid (CLA) with exercise regimes on physical activity in animals
Animal
References
Mizunoya
2005149

et

al.,

Bhattacharya et al.,
2005131
Di Felice et al.,
2007132
Banu et al., 2008209
Zhang et al., 2009210
Kim et al., 2010202
Kim et al., 201218
Hur et al., 2013203
Barone et al., 2013204
Shen et al., 2015211
Mirand et al., 2004212
Faulconnier et al.,
2006213
Mirand et al., 2006133
Salgado et al., 2012134

Resultsd

CLA Supplementation

Strain

Gendera

Formb

Dosagec

Duration

BALB/c
Mice

M

Mixture

0.5%

1 week

BALB/c
Mice
ICR Mice

M

Mixture

0.4%

M

Mixture

C57BL/6
Mice
ICR Mice

F

Mixture

0.425
mg/day
0.5%

M

Mixture

BALB/c
Mice
129 Sv/J
Mice
ICR Mice

M
M

BALB/c
Mice
129 Sv/J
Mice
Wistar
Rats
Wistar
Rats
Wistar
Rats
Wistar
Rats

BFM

LBM

-

↓

-

14 weeks

↓

↓

↑

6 weeks

-

10 weeks

↓

0.5%

18 weeks

↓

Mixture

1.0%

10 weeks

↓

0.5%

6 weeks

↓

↓

F

c9t11/
t10c12
Mixture

1.0%

6 weeks

↓

↓

M

Mixture

0.5%

6 weeks

↓

M

t10c12

0.1%

7 weeks

↓

↓

1.0%

6 weeks

-

-

1.0%

6 weeks

-

↓

1.0%

6 weeks

-

0.5%

10 weeks

↓

M
M
M
F+M

Mixture /
c9t11/t10c12
Mixture /
c9t11/t10c12
Mixture /
c9t11/t10c12
Mixture

a

BW

↑
↓

↑

↑

↑

↓

-

↑ by
Mixture
↑

Exercise
Type
Endurance
(Swimming
& Running)
Endurance
(Running)
Endurance
(Running)
Endurance
(Running)
Endurance
(Swimming)
Endurance
(Running)
Endurance
(Running)
Endurance
(Running)
Endurance
(Running)
Endurance
(Running)

Muscle Metabolism
Energy
Biomarkersf
Expendituree
↓ RER
↑ LPL
↑ Fat oxidation
↔ EE

Endurance
(Running)
Endurance
(Running)
Endurance
(Running)
Endurance
(Swimming)

F, female; M, male.
Mixture, a mixed isomer of cis-9,trans-11 and trans-10,cis-12; c9t11, cis-9,trans-11 CLA isomer; t10c12,trans-10,cis-12 CLA isomer.
c
Dosage (%) means a designated weight percentage of CLA in diet.
d
BW, body weight; BFM, Body fat mass; LBM, lean body mass; -, no change; ↑, increase; ↓, decrease.
e
EE, energy expenditure; RER, respiratory energy ratio; ↔, no change.
f
CPT1, carnitine palmitoyltransferase 1; LPL, lipoprotein lipase; PPARδ, peroxisome proliferator activated receptor δ; UCP2, uncoupling protein 2.

b
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Exercise
Outcome
↑

↑ Muscle
hypertrophy

↔
↑
↑ CPT1 / ↑ UCP2
/ ↑ PPARδ

↑ by
t10c12
↑

↑ Testosterone

↑

Table 2.6. Effects of conjugated linoleic acid (CLA) with exercise regimes on physical activity in humans
Subject

Resultsd

CLA Supplementation
BW

BFM

LBM

Mixture

1.7/3.5/
5.1/6.8

6 and 12
weeks

-

↓ 1.7, 3.4 and
6.8 at 12 wk

↑ 6.8 at
12 wk

F+M

Mixture

1.8

12 weeks

-

↓

Normal /
Overweight

M

Mixture

6.0

4 weeks

-

-

Overweight

F+M

Mixture

3.8

6 months

-

↓

Colakoglu et al.,
200691

Normal

F

Mixture

3.6

6 weeks

↓

↓

↑

Endurance

Pinkoski et al.,
200693

Unknown

F+M

Mixture

5.0

7 weeks

↓

↑

Resistance

Adams et al.,
2006214

Overweight /
Obese

M

Mixture

3.2

4 weeks

-

Nazare et al.,
200797

Normal /
Overweight

F+M

Mixture
(TG)

2.8

14 weeks

-

-

-

Regular
training

Tarnopolsky et
al., 200799

Normal /
Overweight

F+M

Mixture

5.4+5 g
creatine
monohydrate

6 months

-

↓

↑

Resistance

↑

Diaz et
2008101

Overweight /
Obese

F

Mixture

1.8+0.4
mg
creatine
picolinate

12 weeks

-

-

-

Endurance

↔

al.,

Kreider et al.,
200284
Loeffelholz
al., 2003

et

al.,

Overweight /
Obese

F+M

Normal

Formb

Exercise
Outcome
↑

Duration

Thom et
2001123

Gendera

Muscle Metabolism
Energy
Biomarkersf
Expendituree

Dosagec

References
Blankson et al.,
200082

Characteristic

Exercise
Type
Standardized
training
Strenuous

-

↔

Resistance

Resistance

↑

↔ RMR

↑

Resistance

↑ RMR

(Continued)
28

Table 2.6. Continued
Subject
Characteristic

Gendera

Obese

F+M

Mixture

Normal /
Overweight

F+M

Mixture

Chen et al.,
2012109

Overweight /
Obese

F+M

Mixture

Macaluso et al.,
2012110

Normal /
Overweight

M

Bulut et al.,
2013141

Overweight

Jenkins et
al., 2014215,216

References
Cornish et al.,
2009106

Michishita
al., 2010207

Tsao et
2015154

et

al.,

Resultsd

CLA Supplementation
Formb

Exercise
Type
Resistance

Dosagec

Duration

BW

BFM

LBM

4.3+9g
creatine
monohydrate+
36g
whey
protein
1.6+1.52g
amino
acids

5 weeks

-

-

↑

12 weeks

-

-

1.7

12 weeks

↓

↓

-

Resistance

Mixture

4.8

3 weeks

-

-

-

Resistance

M

Mixture

3.0

4 weeks

-

-

-

Endurance

Normal /
Overweight

M

Mixture

5.63

6 weeks

Normal

M

Mixture

3.8

8 weeks

-

a

Muscle Metabolism
Energy
Biomarkersf
Expendituree

Exercise
Outcome
↑

Resistance

↔

↑ Testosterone
in serum

Endurance

↔ PWCFT
↔ VO2 max
↔ GET
↔ RCP

Endurance

↔ RMR

↔

↑ Glycogen
resynthesis /
↑ GLUT4

F, female; M, male.
Mixture, a mixed isomer of cis-9,trans-11 and trans-10,cis-12; c9t11, cis-9,trans-11 CLA isomer; t10c12,trans-10,cis-12 CLA isomer.
c
Dosage (%) means a designated weight percentage of CLA in diet.
d
BW, body weight; BFM, Body fat mass; LBM, lean body mass; -, no change; ↑, increase; ↓, decrease.
e
GET, gas exchange threshold; PWCFT, physical working capacity at the fatigue threshold; RCP, respiratory compensation point; RMR, resting metabolic rate; VO2 max,
maximal oxygen uptake↔, no change.
f
GLUT4, glucose transporter type 4.

b
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↑

skeletal muscle energy metabolism.

2.4 Literature Review Conclusion and Project Rationale
The literature review has discussed that CLA induces a decrease of body fat and an
increase of lean body mass via various regulatory mechanisms. To date, most mechanistic studies
of CLA on body composition change have been focused on adipocyte metabolism in adipose
tissue. However, a growing number of studies highlighting the importance of CLA’s effect on
skeletal muscle metabolism indicate that CLA supplementation may affect skeletal muscle
metabolism representative to increased energy expenditure and enhanced physical activity.
However, the underlying mechanism of how CLA modulates skeletal muscle metabolism has not
been fully discovered. Thus, it is important to investigate the mechanistic study of CLA on
skeletal muscle metabolism including previously well-established signaling pathways such as
mitochondrial biogenesis and muscle fiber type transformation via the AMPK/SIRT1-PGC-1αPPARδ signaling cascade.
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CHAPTER 3
OBJECTIVES OF THE PROJECT
The long-term goal is to develop prevention and/or treatment strategies for obesity and
its related pathologies. The objective of this project is to uncover the mechanisms of CLA on
muscle metabolism. The central hypothesis is that CLA targets the AMP-activated protein kinase
(AMPK) signaling pathway and subsequently the underlying downstream signaling cascades
associated with skeletal muscle metabolism. The rationale of the proposed research is that by
understanding factors contributing to skeletal muscle and physical activity, we will be able to
direct more efficient prevention strategies for obesity and associated chronic diseases in the
future.
The project aims are as follows:
Specific Aim 1: Determine molecular targets of CLA’s effects on muscle metabolism in in
vitro model: The objective of this project is to determine the key molecular mediators of CLA’s
effects on muscle metabolism. The hypothesis to be tested is that CLA modulates AMPK, which
can affect PPARγ coactivator 1α (PGC-1α), and activates the underlying downstream signaling
cascades including mitochondrial biogenesis.
Specific Aim 2: Determine the effects of CLA on physical activity and physiological changes
in skeletal muscle in in vivo models: The objective of this is to determine if CLA influences
voluntary activity and/or endurance exercise capacity in mice through the modulation of
molecular markers in skeletal muscle metabolism. Two hypotheses to be tested are [1] CLA
elicits improved voluntary activity by promoting mitochondrial biogenesis via the modulation of
AMPK signaling pathway and [2] CLA and endurance exercise synergistically improves muscle
metabolism by activating mitochondrial biogenesis and muscle fiber type transformation, leading
to the enhancement of endurance capacity. Specifically, the first hypothesis is tested with two
experimental designs targeting adulthood and childhood obesity.
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CHAPTER 4
CONJUGATED LINOLEIC ACID (CLA) STIMULATES MITOCHONDRIAL
BIOGENESIS SIGNALING BY THE UPREGULATION OF PPARγ
COACTIVATOR 1α (PGC-1α) IN C2C12 CELLS

4.1 Introduction
Skeletal muscle and the corresponding metabolic contributions play a critical role in
maintaining homeostasis in the human body. Skeletal muscle metabolism includes adaptive
responses to physical activity on glucose uptake, fatty acid oxidation, mitochondrial biogenesis
and muscle fiber type shift.177 It is known that these adaptive responses of skeletal muscle involve
a number of regulators, among them AMP-activated protein kinase (AMPK) is the most wellknown molecular target of exercise in skeletal muscle.217 During muscular adaptive responses,
AMPK increases ATP production by controlling a number of transcriptional genes or proteins,
including peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α), peroxisome
proliferator-activated receptors (PPARs) and mitochondria-related proteins. These signaling
cascades play an important role in improving muscle metabolism.5
Mitochondrial biogenesis is one of the adaptive responses in skeletal muscle and is the
process of new mitochondrial formation resulting in direct improvement of energy production
through increasing capacity of respiratory components.218,219 It has been reported that impaired
mitochondrial biogenesis contributes to obesity and related diseases, such as diabetes and
cardiovascular disease through mitochondrial dysfunction and resulting lipid accumulation in
skeletal muscle.220 PGC-1α is known as the primary simulator of mitochondrial biogenesis.
Activated PGC-1α subsequently triggers upregulation of nuclear respiratory factors (NRF-1 and 2) and mitochondrial transcription factor A (Tfam), wherein NRF-1 and -2 play roles in the
expression of a number of nuclear-encoding mitochondrial proteins and Tfam controls
mitochondrial DNA replication and transcription. In turn, these nuclear-encoded markers activate
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mitochondrial proteins and antioxidant enzymes in mitochondria, resulting in mitochondrial
biogenesis.221-224
Conjugated linoleic acid (CLA) is a mixture of geometric and positional conjugated
isomers of linoleic acid (LNA). CLA has shown a variety of beneficial effects such as anticancer, anti-atherosclerosis, antioxidant, and anti-obesity.14 Previously it was reported that CLA
improved voluntary activity and endurance capacity in mice.17,18 There was further support that
modulation of skeletal muscle metabolism by CLA was mediated by increased PPARδ gene
expression 225. In addition, it was previously reported that the c9,t11 CLA isomer induced the
activation of AMPKα in C2C12 skeletal muscle cells,194 however, it was not clear whether CLA
isomers control PGC-1α and subsequent mitochondrial biogenesis. Thus we investigated the role
of CLA isomers on PGC-1α based on AMPK signaling pathway and mitochondrial biogenesisrelated biomarkers to determine its role on mitochondrial biogenesis using C2C12 cells, an
established murine muscle cell line.

4.2 Materials and Methods
4.2.1 Materials
Dulbecco’s Modified Eagle’s Medium (DMEM) and horse serum (HS) were obtained
from Invitrogen (Grand Island, NY). Penicillin/streptomycin mixture, fetal bovine serum (FBS),
and bovine serum albumin (BSA) were purchased from Sigma Aldrich (St. Louis, MO). The
linoleic acid with 99% purity was purchased from Nu-Chek Prep (Elysian, MN). The t10,c12
CLA; c9,t11 CLA; and CLA mixed isomer (Mixture) were obtained from Natural Lipids
(Hovdebygda, Norway). The purity of the t10,c12 CLA preparation was 94 % with 2% c9,t11
isomer and 3% other conjugated linoleic acid isomers. The c9,t11 CLA preparation was 90% pure
and consisted of 4% t10,c12 isomer, 2% other conjugated linoleic acid isomers and 3% oleic acid.
The CLA mixture was 80.7% CLA composed of 37.8% c9,t11, 37.6% t10,c12 and 5.3% other
CLA isomers and 13.7% oleic acid, 3.2% stearic acid, 0.4% palmitic acid and 0.2% linoleic acid.
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Rabbit anti-phosphorylated AMPKα and rabbit anti-AMPK, voltage-dependent anion channel
(VDAC) and superoxide dismutase 2 (SOD2) antibodies were obtained from Cell Signaling
(Berberly, MA). Rabbit anti-PGC-1α, sirtuin 1 (SIRT1), PPARδ, NRF-1, Tfam, cytochrome c
(Cyt C), subunit IV of cytochrome c oxidase (COX IV), glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) and β-actin were purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA). Horseradish peroxidase-conjugated goat anti-rabbit IgG antibody was obtained
from Boston Bioproducts Inc. (Ashland, MA). Other chemicals were purchased from either
Fisher Scientific (Pittsburg, PA) or Sigma Aldrich (St. Louis, MO).

4.2.2 C2C12 Cell Culture
C2C12 mouse myoblasts (CRL-1772™) were obtained from American Type Culture
Collection (Manassas, VA). C2C12 myoblasts were maintained in DMEM containing 10% (v/v)
FBS, 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C in humidified 95% air and 5% CO2
atmosphere. For differentiation the culture medium was switched to DMEM with 2% (v/v) heatinactivated horse serum when myoblasts were 90% confluent. The differentiation medium was
subsequently replaced with fresh medium every two days. After 6 days of differentiation,
myotubes were treated with fatty acids as fatty acid-albumin complexes as previously described.27
Doses and time of treatment are indicated in each figure legend. All treatments included 50 µM
fatty acid free albumin. Concentrations of CLA used reflect the serum levels of CLA after
supplementing 0.5% CLA for 4 weeks in rats or supplementing 0.8-3.2 g per day for 2 months in
humans, which ranged from 23 to 200 µM.27,226 Effects of these fatty acids on cell viability were
determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphnyltetrazolium bromide (MTT) based
assay.227 No significant differences in cell viability were observed in any treatments (data not
shown).
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4.2.3 Western Blot Analysis
The adherent cells were harvested and then lysed with lysis radioimmuno precipitation
assay (RIPA) (50 mM Tris-HCl, 10 Mm NaCl, 5 Mm MgCl2, and 0.5% NP-40, pH 8.0) buffer
(Boston Bioproducts Inc., Ashland, MA) containing protease inhibitor cocktail (Sigma Aldrich,
St. Louis, MO) and phosphatase inhibitor cocktail (Thermo Scientific, Rockford, IL) on ice for 30
min, and centrifuged at 12,000g for 20 min at 4°C. Protein concentration of cell lysate was
determined using the DC protein assay kit (Bio-Rad, Hercules, CA). The lysates were separated
by a 6-15% (w/v) sodium dodecyl sulfate-polyacrylamide gel, transferred to a polyvinylidene
fluoride (Millipore, Bedford, MA). After blocking for 1 h at room temperature (RT), the
membrane was incubated with the primary antibody in TBS-T containing 5% BSA at 4°C
overnight. The membrane was treated with horseradish peroxidase-conjugated goat anti-rabbit
IgG antibody for 1 h at RT. Detection was performed using the enhanced chemiluminescence
solution (Bio-Rad, Hercules, CA) with an Image Station 4000MM (Carestream Health, New
Heaven, CT). GAPDH or β-actin intensity was used for an internal control to normalize protein
content of each sample. Image J software provided by NIH was used to quantify the results.

4.2.4 Quantitative Analysis of Mitochondrial DNA (mtDNA)
Mitochondrial DNA copy number was determined based on method previously
described.228 Total genomic DNA (gDNA) including mtDNA was purified using Puregene® core
kit (Qiagne, Gaithersburg, MD) as described in the manufacturer’s protocol. NADH
dehydrogenase subunit 1 (ND1, Mm04225274_s1) and 18S rRNA (Rn18s, Mm03928990_g1)
with predesigned TaqMan gene expression assay kits were used to represent the mtDNA and the
nuclear DNA (nDNA), respectively. The DNA concentration was diluted to 100 ng/µl, and 1 µl of
DNA was used as a template for the real-time PCR. All reactions were carried out in triplicate
with the StepOnePlus Real-Time PCR System (Applied Biosystems, Foster, CA). The program of
reaction was 2 min at 50°C and 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 1 min
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at 60°C. Quantification of relative mtDNA copy number was assessed by a comparative Ct
method based on analysis of the difference in threshold amplification between mtDNA and
nDNA.

4.2.5 Statistical Analyses
All data in Figures 4.1-4.5 from three independent experiments were collected in
triplicates. Data in Fig. 4.6 are from one experiment. Data in Figures 4.1-4.5 were analyzed by
Two-way analysis of variance (ANOVA) as treatment and experiment as variables, and data in
Figure 4.6 were analyzed by one-way ANOVA, followed by PROC MIXED with Least Square
Means options of the SAS software for Windows release 9.2 (SAS Institute Inc., Cary, NC) on
the W32_VSHOME platform. The experimental groups were compared by multiple comparisons
based on the Dunnett’s test. Data are presented as mean ± S.E. P values < 0.05 are reported as
statistically significant.

4.3 Results
4.3.1 Effect of CLA Isomers on AMPK Signaling Pathway in C2C12 Skeletal Muscle Cells
Based on previous reports that CLA upregulated PPARδ and AMPK expressions,18,194,196
we first determined the effect of CLA isomers on AMPK signaling pathway (Fig. 4.1). The
relative expression levels of total AMPKα were not different in all treatments compared to
control (Fig. 4.1B). However, treatments with the t10,c12 CLA isomer or the CLA mixture
significantly upregulated phosphorylation of AMPKα compared to control (Fig. 4.1C). As a
result, increased ratio of phosphorylated AMPKα to total AMPKα by the t10,c12 isomer and the
CLA mixture were observed (Fig.4.1D). However, no differences were observed by either
linoleic acid or the c9,t11 CLA isomer compared to control in these parameters.
Along with AMPK, SIRT1 is also known to be involved in activation of PGC-1α by
deacetylation independent to AMPK.185 There were no differences in the expressions of SIRT1 by
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all treatments (Fig.4.2). These data suggest that CLA, particularly the t10,c12 isomer, controls
AMPKα to regulate PGC-1α, but not via SIRT1.

4.3.2 Effect of CLA Isomers on PGC-1α Expression
We next examined the effects of CLA isomers on the expressions of PGC-1α, which is one of the
downstream target proteins of AMPK and also plays a central role in regulation of mitochondrial
biogenesis.182 Both CLA isomers, c9,t11 and t10,c12, and the CLA mixture significantly
increased the protein expression levels of PGC-1α compared to control (Fig. 4.3). Linoleic acid
itself did not significantly increase expression of PGC-1α over control. These results suggest that
CLA may stimulate mitochondrial biogenesis via PGC-1α-mediated signaling cascades.

Figure 4.1 Effect of conjugated linoleic acid (CLA) isomers on protein expression levels of AMPactivated protein kinase α (AMPKα) in C2C12 cells.
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Figure 4.2 Effect of conjugated linoleic acid (CLA) isomers on the relative expression levels of
sirtuin1 (SIRT1) in C2C12 cells.

Figure 4.3 Effect of conjugated linoleic acid (CLA) isomers on peroxisome proliferator-activated
receptor γ coactivator 1-α (PGC-1α) expression in C2C12 cells.

4.3.3 Effect of CLA Isomers on Mitochondrial Biogenesis-related Biomarkers
The effects of CLA on mitochondrial biogenesis were measured through PPARδ, NRF-1
and Tfam primarily controlled by PGC-1α.229,230 The CLA mixture significantly increased
expression of PPARδ compared to control, while the c9,t11 or t10,c12 isomer or linoleic acid did
not show any significant effect compared to control (Fig. 4.4B). Among nuclear respiratory

38

factors (NRF-1 and -2), NRF-1 is more specifically related to mouse Tfam, we thus analyzed the
expression level of NRF-1 instead of NRF-2.231 Both c9,t11 and t10,c12 CLA isomers
significantly upregulated NRF-1 expression compared to control (Fig. 4.4C). Furthermore,
expression of Tfam was significantly increased after treatments of all individual CLA isomers
compared to control, while linoleic acid itself did not have any effect compared to control (Fig.
4.4D). Collectively, these data from mitochondrial biogenesis-related biomarkers suggest that
c9,t11 and t10,c12 CLA isomers may have a positive effect on mitochondrial biogenesis through
modulating NRF-1 and Tfam.

Figure 4.4 Effect of conjugated linoleic acid (CLA) isomers on mitochondria-related factors in
C2C12 cells.

4.3.4 Effect of CLA Isomers on Mitochondrial Content
Overall mitochondrial relative content can be indirectly estimated by determining the
expression levels of cytochrome c and COX IV located in the inner membrane of mitochondria
and VDAC localized in the mitochondrial outer membrane.232,233 The c9,t11 CLA isomer
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significantly increased the expression of cytochrome c (Fig. 4.5B). On the other hand, the t10,c12
CLA isomer showed significantly increased VDAC expression compared to control (Fig. 4.5D).
No significant effects by linoleic acid were observed on cytochrome c or VDAC. To assess
mitochondrial function, we also measured the expression level of SOD2, manganese superoxide
dismutase (MnSOD), which is one of the genes encoding mitochondrial protein in the inner
mitochondrial matrix and protect mitochondria from reactive oxygen species.234 In this study, no
significant effects were observed by any treatment on expression level of SOD2 (Fig. 4.5E).

Figure 4.5 Effect of conjugated linoleic acid (CLA) isomers on mitochondrial content in C2C12
cells.
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We further determined the ratio between mtDNA and nDNA as an indicator of
mitochondrial replication. Both CLA isomers, c9,t11 and t10,c12, as well as the CLA mixture
significantly increased the ratio mtDNA/ nDNA compared to control, whereas linoleic acid
showed no significant difference over control (Fig. 4.6). Taken together, our observations indicate
that both CLA isomers induce the increase of mitochondrial DNA replication, although
mitochondrial components may be increased in isomer-dependent pathways.

Figure 4.6 Effect of conjugated linoleic acid (CLA) isomers on mitochondrial DNA (mtDNA)
copy number in C2C12 cells.

4.4 Discussion
In this study, we demonstrated that CLA activated several key biomarkers in
mitochondrial biogenesis signaling cascade in C2C12 murine skeletal muscle cells. Of particular
importance the c9,t11 and t10,c12 CLA isomers targeted PGC-1α and triggered the activation of
downstream proteins such as NRF-1 and Tfam, as well as upregulating PPARδ (the CLA
mixture), resulting in modulation in mitochondrial biogenesis. These results suggest that both
CLA isomers stimulate mitochondrial biogenesis and this can help explain improved activity and
endurance capacity in mice fed CLA reported in previous publications.17,18
Several studies have demonstrated the effect of polyunsaturated fatty acids such as
docosahexaenoic acid (DHA) and the t10,c12 CLA isomer on enhanced glucose uptake and fatty
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acid β-oxidation through AMPK upregulation in murine skeletal cells.196,235,236 However,
mechanisms of these polyunsaturated fatty acids on downstream signaling cascade from AMPK
are not clear yet. It is reported that AMPK is required for regulation of PGC-1α in skeletal muscle
and PGC-1α is the most promising target to regulate mitochondrial biogenesis.182,237 Moreover,
PGC-1α-NRF-1/-2-Tfam cascade is generally accepted as mitochondriogenic pathway, even
though there are various PGC-1α-dependent downstream cascades.229 Our results here support
that CLA modulates PGC-1α via AMPK signaling cascades and resulting mitochondrial
biogenesis-related molecular markers through PGC-1α-NRF-1-Tfam. In addition, lack of effects
on SIRT1 by CLA is consistent with the previous reports that SIRT1 was not required for
mitochondrial biogenesis through PGC-1α activation.238 However, we cannot conclude whether
CLA directly targeted AMPK or acted indirectly via upstream regulators of AMPK such as liver
kinase B1 (LKB1) and Ca2+/calmodulin-dependent protein kinase (CaMK) with current results.
Therefore, additional studies are needed to confirm the primary targets of CLA for this activity,
particularly upstream regulators of AMPK.
The c9,t11 CLA is the predominant natural CLA form comprising approximately 80% of
the total isomers in dairy and meat products from ruminants, while synthetic CLA for commercial
preparations is typically a 50:50 mixture of c9,t11 and t10,c12 CLA isomers.15 Most biological
effects of CLA are known to be results of independent or additive effects, however, there are few
reports that these two CLA isomers interact.142 For muscle metabolism, previous studies report on
the effects of c9,t11, t10,c12 CLA and CLA mixed isomers on AMPK in skeletal muscle
cells.194,195 Our data illustrated that the t10,c12 isomer and the CLA mixture upregulated AMPK
activity independent of the c9,t11 isomer. This is inconsistent with observations by Qin et al.194
that the c9,t11 isomer increased the expression of AMPK in a dose and time dependent manner.
This discrepancy may be in part due to methodological differences; they examined only c9,t11
isomer treatment (without t10,c12 or CLA mixed isomers) compared to control and all their
treatments were combined with palmitate. In addition, our observations were consistent with the
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results of Mohankumar et al.195 that t10,c12 but not c9,t11 CLA stimulated phosphorylation of
AMPK in a time-dependent manner, although they used a different cell line (L6 myotube) and
shorter incubation time (30 min).
In the current results, we observed both CLA isomers increased expression of PGC-1α,
although only the t10,c12 CLA isomer, but not the c9,t11 isomer, activated AMPK (Fig 4.1).
Previously Parra et al.198 reported that a commercial CLA mixture upregulated PGC-1α gene
expression in C57BL/6J gastrocnemius muscle although it is not clear if both isomers have effects
on PGC-1α in this study. Thus, it is possible that there is an additional mechanism contributing to
the c9,t11 isomer’s effects on PGC-1α, possibly via LKB1 and CaMK.183
PPARδ is abundant in skeletal muscle and is a primary target gene for preventing
obesity and improving physical activity through modifying muscle morphology and enhancing
oxidative capacity.192 Previously it was reported that the t10,c12 CLA isomer upregulated mRNA
level of PPARδ in trained 129 Sv/J mice gastrocnemius muscle.18 In the current study, the CLA
mixture, but not the c9,t11 or t10,c12 isomer, showed significant differences in PPARδ
expression compared to control. This observation is similar to a study by Oraldi et al.199 that the
CLA mixed isomers increased both transcriptional and translational levels of PPARδ in C2C12
cells. It is not clear why the individual CLA did not significantly influence expression of PPARδ
in the current study. These discrepancies may derive from differences in experiments, in vivo vs.
in vitro, and the presence or absence of an exercise regime for the in vivo study. Although a few
methods mimicking exercise training, for example electrical pulse stimulation, are used for in
vitro testing, this model still has unavoidable limitations.
We also tested effects of CLA isomers on the expression levels of NRF-1 and Tfam
(both known to modulate mitochondrial biogenesis221) as downstream regulators of PGC-1α.
Tfam activation regulates the expression of mitochondrial DNA encoded oxidative respiratory
phosphorylation proteins, resulting in the induction of increased mitochondrial contents and
functions 239. In this study, CLA isomers induced NRF-1 activation as well as Tfam, a
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downstream marker from NRF-1, which was significantly activated by both c9,t11 and t10,c12
CLA isomers. This suggests that CLA may increase mitochondrial biogenesis via the universal
signaling cascade, PGC-1α-NRF-1-Tfam,221 and is further supported by the finding that
mitochondrial DNA copy number significantly increased after CLA treatments (Fig. 4.6).
In the current study, we tested effects of CLA isomers on several mitochondrial markers,
cytochrome c, COX IV and VDAC. The expression levels of cytochrome c, COX IV and VDAC
indirectly represents whether tissues or cells are undergoing mitochondrial biogenesis.232 In
particular, cytochrome c is involved in oxidative capacity through phosphorylation, while VDAC
is known to be linked to mitochondrial dysfunction and aging as well.240 Our results suggest that
the c9,t11 isomer increased expression of cytochrome c, while t10c12 isomer increased
expression of VDAC. The former observation is consistent with Mollica et al.241 that the c9,t11
isomer, but not the t10,c12 isomer, induced higher cytochrome c activity in Wistar rats. There are
currently no reports of CLA’s effect on VDAC, however, it was reported that other
polyunsaturated fatty acids, DHA and eicosapentaenoic acid (EPA), did not increase VDAC
expression in male Wistar rats.242 This is the first report that t10,12 CLA significantly increase
VDAC expression in C2C12 cells, which may provide evidence to have more mitochondria. Also
our results suggest that individual CLA isomers might selectively activate mitochondrial proteins
associated with mitochondrial biogenesis, resulting in stimulation of mitochondriogenic
signaling. In addition, although cytochrome c, COX IV and VDAC represent mitochondrial
components as an indirect marker for mitochondrial biogenesis, we cannot rule out the possibility
that CLA may influence other mitochondrial-related factors, such as COX I, II and III subunits
and ATP synthase subunits in C2C12 myotubes.243
PGC-1α is also involved in the induction of ROS-detoxifying enzymes such as SOD2 in
mitochondria.224 The c9,t11 CLA isomer increased the mRNA level of SOD2 in earlier studies of
CLA-treated in Sprague-Dawley rats and THP-1 macrophages,152,244 although we did not observe
any differences due to individual CLA isomers on SOD2. These discrepancies may result from
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differences in experimental models used, i.e. dietary supplement to animals with exercise and
cells with an oxidative stressor.
In conclusion, both CLA isomers were shown to activate PGC-1α, which was linked with
upregulation of mitochondrial biogenesis. It is likely that the t10,c12 isomer activates PGC-1α
through AMPK phosphorylation and the c9,t11 isomer stimulates PGC-1α via another
undetermined pathway as c9,t11 isomer does not activate phosphorylated AMPK. Both c9,t11
and t10c12 CLA isomers enhance the expression of NRF-1 and Tfam. Also the CLA mixture
improves PPARδ expression. It is supporting that all CLA treatments significantly increase
mitochondrial DNA replication. Taken together, CLA engages the mitochondrial biogenesis
process through modulating PGC-1α-NRF-1-Tfam cascade without any isomer interaction.
Overall, CLA may play a role as a stimulator of mitochondrial biogenesis.
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CHAPTER 5
CONJUGATED LINOLEIC ACID (CLA) IMPROVES MUSCLE METABOLISM
VIA STIMULATING MITOCHODNRIAL BIOGENESIS SIGNIALING IN
GENETICALLY INDUCED INACTIVE ADULT-ONSET OBESE MICE

5.1 Introduction
Reduced energy expenditure, particularly associated with lack of physical activity, plays a
significant role in weight gain.245 However, overall physical activity can be influenced by
complex issues, and thus make it difficult to use as universal means to control/prevent obesity.246
Previously nescient helix-loop-helix 2 wild type (N2KO) mouse model has been established,
where these animals exhibit reduced activity at a certain age, 7-10 weeks old, without
hyperphagia during preobese period. Targeted deletion of the Nhlh2 transcription factor
expressed in the hypothalamus precedes adult-onset obesity in mice, contributing to a disruption
of the hypothalamic-pituitary axis.247,248 Thus, N2KO mice represent an animal model that mimics
induction of adult-onset obesity, making it particularly useful to investigate any compounds that
target activity in these animals.
Conjugated linoleic acid (CLA) is a mixture of geometric and positional conjugated
isomers of linoleic acid. The effects of CLA have been previously demonstrated as to influence
on development of cancer and atherosclerosis, as well as preventing osteoporosis and modulating
immune responses.13,14 Moreover, CLA has drawn special attention in the last two decades for its
anti-obesity effect through various mechanisms, such as regulation of energy and lipid
metabolism, adipogenesis, inflammation and adipocyte apoptosis.15,16 In addition, it was reported
that CLA improved voluntary activity and endurance capacity in animal models, including N2KO
animals, and CLA modulated energy metabolism, especially uncoupling protein 2 (UCP2) and
peroxisome proliferator-activated receptor δ (PPARδ) in skeletal muscle.17,18 However, it is
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currently not fully understood how CLA influences skeletal muscle metabolism, including
mitochondrial biogenesis.
Mitochondrial biogenesis is composed of complex long-term adaptive responses in skeletal
muscle.249 It is known that mitochondrial biogenesis is important for endurance capacity but also
plays a significant role in proper weight management.10,220 In fact, CLA isomers, cis-9,trans-11
and trans-10,cis-12, stimulated the key molecular markers involved in mitochondrial biogenesis
and increased mitochondrial DNA copy number.250 Also, it was previously reported that CLA
increased voluntary activity and endurance capacity as well as reduced obesity. Thus, we
investigated the role of CLA on skeletal muscle energy metabolism and mitochondrial biogenesis
using N2KO mice to understand its underlying mechanisms on weight control.

5.2 Materials and Methods
5.2.1 Materials
CLA was provided by Natural Lipids Ltd. AS (Hovdebygda, Norway). The CLA content
of the preparation used was 80.7%. CLA consisted of 37.8% cis-9,trans-11, 37.6% trans-10,cis12 and 5.3% other CLA isomers and the remainder of the preparation was 13.7% oleic acid, 3.2%
stearic acid, 0.4% palmitic acid and 0.2% linoleic acid. Semi-purified powdered diet (TD07518,
95% basal mix) was purchased from Harlan Laboratories (Madison, WI). Serum triacylglyceride
(TG), glucose, and total cholesterol assay kits were purchased from Genzyme Diagnostics
(Charlottetown, PE, Canada). DC protein assay kit was from Bio-Rad (Hercules, CA). Rabbit
antibodies for phosphorylated AMP-activated protein kinase α (AMPKα), AMPKα, voltagedependent anion channel (VDAC) and superoxide dismutase 2 (SOD2) were obtained from Cell
Signaling (Berberly, MA). Rabbit antibodies for peroxisome proliferator-activated receptor γ
coactivator 1α (PGC-1α), sirtuin 1 (SIRT1), PPARδ, nuclear respiratory factor 1 (NRF-1),
mitochondrial transcription factor A (Tfam), cytochrome c (Cyt C), cytochrome c oxidase subunit
4 (COX IV), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β-actin were purchased
47

from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Horseradish peroxidase-conjugated goat
anti-rabbit IgG antibody was from Boston Bioproducts Inc. (Ashland, MA). Other chemicals used
were purchased from either Sigma Chemical Co. (St. Louis, MO) or Fisher Scientific (Pittsburg,
PA).

5.2.2 Animal and Diet
All animal work was done in compliance with the Institutional Animal Care and Use
Committee at the University of Massachusetts, Amherst. 129Sv/J heterozygous for Nhlh2 male
and female mice between 8 and 52 weeks of age were used as breeders to prepare for wild type
and Nhlh2 knock-out offspring (N2KO). Based on the results from genotyping at weaning,247
eight female wild type and six N2KO mice were placed in wire-bottomed cages with a 12:12 h
light:dark cycle. During a 2-week acclimation period, mice were fed a control diet (20 w/w% fat)
and were subjected to baseline test for glucose tolerance and voluntary movement. At the end of
the adaptation period, animals were divided into two groups per each genotype based on their
body weight. Either control (high-fat, 20 w/w% fat) or 0.5% CLA containing high-fat diet was
provided for 10 weeks. Diets and water were available ad libitum. The diet composition is shown
in Table 5.1. Body weight and food intake were monitored weekly. At the end of study, the mice
were fasted for 4 h, and sacrificed by CO2 asphyxiation. Blood was collected by cardiac puncture
and internal organs (liver, heart, kidney, spleen, adipose tissues including parametrial,
retroperitoneal and mesenteric fats and gastrocnemius muscle) were also weighed.

5.2.3 Voluntary Movement Measurement (Non-exercise Physical Activity Test)
Voluntary movement was recorded using LoliTrack Quatro Video Tracking Software
Version 1.0 (Loligo Systems, Tjele, Denmark) with a high-resolution camera supported to
monitor under dim light. Animals were individually placed into a cage during the dark cycle
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Table 5.1. Composition of experimental diet for control and conjugated linoleic acid (CLA) groups.
Ingredient

g/kg

Casein, ‘vitamin-free’ tested

169.1

L-Cystine

2.2

Sucrose

100

Cornstarch

288.5

Maltodextrin

132

Cellulose

50

Soybean oil

195

CLA or Soybean oil

5

Mineral mix, AIN-93M-MX (TD 94049)

42.8

Vitamin mix, AIN-93-VX (TD 94047)

12.4

Choline bitartrate

3

tert-Butylhydroquinone

0.04

Total

1,000

(5:00pm-5:00am) once biweekly with free access to diet and water (provided as HydroGel,
Clear H2O, Portland, ME). The cage (30 × 46 × 40 cm) used for activity monitoring is larger than
the typical cage to measure proper movement, since the small cage is known to limit voluntary
movements.251 Movement data for 8 h (7:00pm-3:00am) was analyzed excluding the first 2 h
(5:00pm-7:00pm) of early phase and 2 h (3:00am-5:00am) of late phase, due to early adaption
and due to lack of movement, respectively.

5.2.4 Serum Parameters
Serum was separated by centrifugation at 3,000 g for 20 min at 4°C. Serum samples
were used for determination of TG, glucose and total cholesterol using commercial kits following
by the manufacturer’s instruction.
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5.2.5 Glucose Tolerance Test
Intraperitoneal glucose tolerance test (IGTT) was performed every four weeks as
described previously252 with some modification. Glucose levels were measured using a blood
glucose meter, Advocate Redi-Code+ (Advocate Meters Inc., Dorado, Puerto rico). All mice were
fasted for 6 h before IGTT, and glucose levels were monitored from the tail vein at 0 min for
baseline measurement. Then a 30% glucose solution (2.0g glucose/kg body weight) was
administered by intraperitoneal injection. Blood glucose levels were monitored at 15, 30, 60, 90
and 120 min post glucose injection. The areas under the curve (AUC) were calculated using
SigmaPlot 11.0 (Systat Software, Inc., San Jose, CA).

5.2.6 Western Blot Analysis
Gastrocnemius skeletal muscle tissue was ground with liquid nitrogen, prepared for 50
mg aliquots and stored at -80°C until analysis. Each sample was homogenized in lysis
radioimmune precipitation assay (RIPA) (50 mM Tris-HCl, 10 mM NaCl, 5 mM MgCl2, and
0.5% NP-40, pH 8.0) buffer (Boston Bioproducts Inc., Ashland, MA) containing protease
inhibitor cocktail (Sigma Aldrich, St. Louis, MO) and phosphatase inhibitor cocktail (Thermo
Scientific, Rockford, IL) and then lysed on ice for 2 h, and centrifuged at 12,000g for 20 min at
4°C. Protein concentration of tissue lysate was determined using the DC protein assay kit. The
lysates were separated by an 8-15% (w/v) sodium dodecyl sulfate-polyacrylamide gel and
transferred to a polyvinylidene fluoride membrane (Millipore, Bedford, MA). After blocking for
1 h at room temperature (RT), membranes were incubated with appropriate primary rabbit
antibodies in 0.05% Tween-20 in tris-buffered saline (TBS-T) containing 5% bovine serum
albumin at 4°C overnight. After washing, membranes were treated horseradish peroxidaseconjugated goat anti-rabbit IgG antibody for 1 h at RT. Detection was performed using the
Enhanced Chemiluminescence solution (Bio-Rad, Hercules, CA) with an Image Station 4000MM
(Carestream Health, New Heaven, CT). GAPDH or β-actin intensity was used for an internal
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control to normalize protein content of each sample. Image J software was used to quantify the
results.

5.2.7 Statistical Analyses
Data were analyzed by two-way analysis of variance (ANOVA) followed by PROC
MIXED with Least Square Means options of the SAS software (Version 9.3, SAS Institute Inc.,
Cary, NC, USA). For the body weight, food intake, voluntary movement and glucose tolerance
test, two-way ANOVA and repeated measures with PROC MIXED were performed. In the
repeated measures using PROC MIXED, we found that the assumption of constant variance did
not appear to hold for the trend of voluntary movement. Thus, data were converted into
logarithm-scale and used for analysis. For internal organ, adipose tissue weight, serum parameters
and the log-transformed relative protein expression level data two-way ANOVA with PROC
MIXED were used. The Tukey-Kramer’s method in SAS was used for the multiple comparisons
among the experimental groups. Data are shown as the mean ± S.E. P values less than 0.05 are
reported as statistically significant.

5.3 Results
5.3.1 Body Weights and Food Intake
Body weight and food intake data are shown in Figure 5.1A and 1B. N2KO mice started
to show greater body weight than wild type mice at week 5 (10-week-old) and maintained this
trend to the end of the experiment (overall genotype effect, P < 0.0001). Furthermore, CLA fed
animals showed significant reduction in body weight (overall CLA effect, P = 0.042). Greater
effects of CLA on body weight were observed in N2KO animals compared to wild type animals,
when significance was observed starting at week 6 between N2KO control and N2KO CLA
groups (Fig. 5.1A). No significant differences were observed in food intakes between any of
groups (Fig. 5.1B).
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5.3.2 Tissue Weights
Total adipose tissue weight including parametrial, mesenteric, and retroperitoneal
adipose tissue, liver, heart, kidney, spleen and gastrocnemius skeletal muscle tissue weights are
shown in Table 5.2. N2KO control animals had the most adipose depots among all treatment

Figure 5.1 Effect of conjugated linoleic acid (CLA) on body weight (A) and food intake (B) in
wild type and N2KO mice.

groups. Adipose tissue weights except mesenteric fat were significantly different by genotype,
while significant interaction between diet and genotypes were observed in mesenteric adipose
tissue weights. Only retroperitoneal fat weights but not others showed significantly difference by
CLA supplementation (P = 0.0055).
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The gastrocnemius skeletal muscle weights were significantly increased with CLA (P =
0.0282), along with significant genotype effects (P < 0.0001). No interactions were observed for
diets and genotypes in muscle weights. Both genotype and CLA had significant effects on kidney
weights. Liver, heart and spleen weight were influenced by CLA significantly, but not by
genotypes.

Table 5.2. Effects of conjugated linoleic acid (CLA) on organ weights in wild and N2KO mice.

Values represent means ± S.E. (n = 3-4). a-bMeans with different superscripts within the same row are
significantly different (P < 0.05). P-values in table are from two-way ANOVA. N2KO, nescient helix-loophelix knock-out mice; CLA, conjugated linoleic acid; n.s., not significant.

5.3.3 Voluntary Movement Measurement (Non-exercise Physical Activity Test)
Effects of CLA on physical activity were determined by measuring voluntary movement
(non-exercise physical activity) biweekly (Fig. 5.2A-F). Data in Figures 5.2A-F were plotted over
time (Fig. 5.2G-I). Data were represented as total (19:00-03:00) as well as two different time
periods, early (19:00-23:00) and late (23:00-03:00). As reported previously,205,253 N2KO mice
showed significantly decreased travel distances compared to wild type animals over time (overall
genotype effects, P < 0.0001), meanwhile CLA treatment significantly increased total
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Figure 5.2 Effect of conjugated linoleic acid (CLA) on voluntary movement (non-exercise
physical activity) in wild type and N2KO mice.

travel distance (P = 0.0172). No interactions among genotype, diet and time were observed.
Intriguingly, voluntary movements during the late phase in control diet-fed mice were
significantly reduced compared to CLA-diet groups (P = 0.0022), whereas during the early phase
there was no significant CLA effect on travel distances in all treatment groups. In Figures 5.2G-I,
it was evident that control N2KO mice showed declining activity in total as well as early and late
phase over time, while CLA-fed N2KO mice either did not display reduced activity or slightly
increased voluntary movement during the same time period.
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5.3.4 Glucose Tolerance Test
To evaluate whether CLA treatment affects glucose homeostasis, we completed glucose
tolerance tests every four weeks (Fig. 5.3). There were no significant differences among all
treatment groups at each time point. However, there were significant overall time effects (P <
0.0001), which suggests potential impaired glucose tolerance due to high-fat diet over ageing in
these animals regardless of diet or genotype effects.

Figure 5.3 Effect of conjugated linoleic acid (CLA) on glucose tolerance in wild type and N2KO
mice.

5.3.5 Serum Parameters
Results of serum parameters are shown in Table 5.3. N2KO animals had higher levels of
serum TG than wild type mice (P = 0.0003), with overall CLA effects on TG observed (P =
0.0408). No interactions were observed for TG on genotypes and CLA effects. Consistent with
glucose tolerance results during the experimental period, no difference in the levels of glucose
was observed among all experimental groups. Significant interaction between genotypes and
CLA was observed in total cholesterol level (P=0.0080).
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Table 5.3. Effects of conjugated linoleic acid (CLA) on serum parameters in wild and N2KO mice.

Values represent means ± S.E. (n = 3-4). a-bMeans with different superscripts within the same row are
significantly different (P < 0.05). P-values in table are from two-way ANOVA. N2KO, nescient helix-loophelix knock-out mice; CLA, conjugated linoleic acid; n.s., not significant.

5.3.6 Effects on Muscle Metabolism
To determine whether CLA treatment influences skeletal muscle metabolism, we
investigated the effect of CLA on AMPK signaling pathway (Fig. 5.4A and B). There were no
differences in all treatments in the relative expression levels of total AMPKα, a master sensor to
maintain energy homeostasis. However, significant effects of CLA on phosphorylation of
AMPKα (the active form of AMPKα) compared to the control groups were observed (P = 0.0291
for overall CLA effect). As a result, increased ratio of phosphorylated AMPKα to AMPKα was
shown in CLA-fed animals (P = 0.024 for overall CLA effect). Another key biomarker, SIRT1, a
NAD-dependent deacetylase inducing PGC-1α activation, was not significantly different in all
treatment groups. However, expression of PGC-1α, a master regulator of mitochondrial
biogenesis, was increased slightly in N2KO CLA animals compared to respective control,
although it did not reach significance (Fig. 5.4B).

5.3.7 Effects on Mitochondrial Biogenesis-related Factors
Based on the evidence that CLA potentiates activation of AMPKα and PGC-1α in
N2KO mice in Fig. 5.4, we evaluated whether CLA treatment was involved in mitochondrial
biogenesis in the gastrocnemius muscle. Mitochondrial biogenesis plays a key role in increasing
oxidative capacity, thus reduces muscle fatigue, resulting in prolonged endurance capacity.249 We
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Figure 5.4 Effect of conjugated linoleic acid (CLA) on protein expression of AMP-activated
protein kinase (AMPK), SIRT1, and PGC-1α from the gastrocnemius muscle in wild type and
N2KO mice.

have tested PPARδ, NRF-1 and Tfam in the gastrocnemius muscle, all of them are well-known
markers for mitochondrial biogenesis that are primarily controlled by PGC-1α.229,230,254 As
expected, supplementation with CLA significantly increased the expression levels of PPARδ
compared to control-fed animals (P = 0.0215 for overall CLA effect), which is a marker
associated in mitochondrial biogenesis as well as muscle type transformation. The expression
levels of NRF-1, a regulator to mediate nuclear-encoding mitochondrial proteins, were not
different in all experimental groups. Expression of Tfam, an important regulator for
mitochondrial DNA replication and transcription, was upregulated by CLA-supplementation in
comparison to controls (P = 0.0225 for overall CLA effect) in both genotype animals (Fig. 5.5A
and B).
We further investigated expression levels of mitochondrial proteins, cytochrome c and
COX IV located in the inner membrane of mitochondria and VDAC localized in the outer
mitochondrial membrane.232 Also, we measured expression of manganese superoxide dismutase
(SOD2), which encodes a mitochondrial matrix protein and protects mitochondria from reactive
oxygen species, to assess mitochondrial function.234 Among them cytochrome c protein levels
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Figure 5.5 Effect of conjugated linoleic acid (CLA) on mitochondrial biogenesis-related factors
from the gastrocnemius muscle in wild type and N2KO mice.

were significantly increased in wild type animals (P = 0.0069 for overall genotype effect). The
expression levels of VDAC slightly increased in CLA-fed mice compared to control groups. No
significant differences were observed in COX IV and SOD2 (Fig. 5.6A and B).

Figure 5.6 Effect of conjugated linoleic acid (CLA) on mitochondrial content and function from
the gastrocnemius muscle in wild type and N2KO mice.
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5.4. Discussion
In the current study, we have demonstrated that CLA treatment prevents body weight
gain and improves voluntary movements through modulating the key molecular markers related
to muscle metabolism via stimulating mitochondrial biogenesis signaling in adult-onset inactivity
induced obese mice. Of particular importance CLA-fed mice were shown to activate AMPKα,
PGC-1α, and subsequently upregulate mitochondria-related molecular markers, such as PPARδ
and Tfam in both wild type and N2KO mice. These observations further support that CLA
supplementation helps improve physical activity, and change body composition including
increased lean body mass in previous animal studies.15,17,27,31,63,205 This is the first report that CLA
treatment may lead to preventing the development of obesity in adult-onset inactivity induced
obese mice by stimulating mitochondrial biogenesis.
Mitochondria is one of the key cellular compartments generating energy requires for
cells and may play a significant role in maintaining energy balance and contribute to attenuating
the development of obesity. The process of formation of mitochondria, mitochondrial biogenesis,
is a complicated process and regulated by numerous different upstream signals, however, it is
well-established that PGC-1α is a primary master regulator of mitochondrial biogenesis.218,219,222
Activated PGC-1α subsequently triggers upregulation of nuclear and mitochondrial genes and
proteins such as PPARδ, NRF-1 and -2, and Tfam, which lead to mitochondrial biogenesis.229 It is
further supported that PGC-1α is involved in physical activity and promotes the formation of
oxidative slow-twitch muscle fibers resulting in enhanced endurance capacity and improved
exercise tolerance.190,255 The current results suggest that CLA may potentiate mitochondrial
biogenesis via PGC-1α, particularly in N2KO animals. Also increased voluntary activity levels
resulting from CLA supplementation may have modulated muscle metabolism through the
upregulation of PGC-1α expression. However, further confirmatory studies are needed, including
changes of morphological and histological properties of skeletal muscles with regard to fiber type
transformation from fast (glycolytic) to slow-twitch (oxidative).
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To further understand whether increased PGC-1α activity with CLA was directly
influenced or not, we further investigated the upstream activators of PGC-1α; phosphorylation by
AMPKα and deacetylation by SIRT1 5. CLA treatment significantly upregulated the expression of
phosphorylated AMPKα (active form of AMPKα) but not SIRT1 activity, suggesting that the
influence of CLA on AMPKα activation is more important than that of SIRT1.194-196,238
Although PGC-1α facilitates various molecular events, PGC-1α-NRF-1/-2-Tfam and
PGC-1α-PPARδ signaling cascade are important mitochondriogenic pathways.186,256 PPARδ plays
a critical role in regulation of muscle fiber type transformation and improvement of endurance
capacity by stimulating mitochondrial functions including mitochondrial biogenesis.192,257 It was
previously reported that the trans-10,cis-12 CLA isomer increased mRNA expression level of
PPARδ in exercise-trained 129 Sv/J mice gastrocnemius skeletal muscle.18 Consistently, the
current results support that CLA supplementation upregulated PPARδ expression in both N2KO
and wild type mice.
Alternatively, PGC-1α regulates NRF and Tfam. NRF-1 and -2 play significant roles in
the expression of nuclear-encoding mitochondrial genes and proteins and Tfam controls the
expression of mitochondrial DNA encoded oxidative respiratory phosphorylation proteins. Their
activation results in increased mitochondrial mass and functions.239,258,259 In the current study
CLA treatment activated Tfam, which is reported to be closely linked with activation of
AMPKα.182,260 Taken together, the current results suggest that CLA promotes mitochondrial
biogenesis through AMPKα-PGC-1α-PPARδ and/or -Tfam.
Upregulation of cytochrome c, a nuclear-encoded protein of the electron transport chain,
has been previously reported in other food bioactive compounds, quercetin and isoflavones.260,261
In this study, CLA supplementation resulted in increased cytochrome c, potentially mediated by
increased upstream signaling pathway as described above. However, our current results cannot
rule out the possibility that CLA may also influence other regulatory mechanisms for cytochrome
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c, such as the early growth response gene-1 (EGR1), specificity protein 1 (Sp1) and
thrombospondin-1 receptor CD47.262-264
The targeted deletion of Nhlh2 yields a unique mouse model for inducing obesity, not by
increasing food consumption or lowering basic metabolic rate compared to wild type animals but
by reducing overall physical activity levels.247,254 Thus, reduced physical activity in N2KO
animals plays a crucial role in induction of weight gain and fat accumulation. Consistent with
previous publications,205,247,253 we observed no difference in food intake between all treatment
groups during the entire experimental period, while N2KO mice reduced voluntary activity and
increased body weight gain compared to wild type animals.
Although not significant, we observed CLA treatment marginally contributed to glucose
intolerance. It has been suggested that increased fatty acid β-oxidation by CLA might result in
glucose intolerance, as proposed “the glucose-fatty acid cycle”.265 In fact, it is known that
increased AMPK activity induces acetyl-CoA carboxylase inactivation, and subsequently results
in decreasing accumulation of malonyl-CoA, which in turn leads to increased fatty acid βoxidation in mitochondria through the induction of upregulated CPT-1 expression.266,267 Enhanced
fatty acid β-oxidation results in citrate accumulation in the cytosol, which causes inhibition of
glucose transporter 4 and 6-phosphofructo-1-kinase.268 In fact, it has been previously shown that
CLA increased CPT-1 expression and activities.17,18,63 Moreover, relatively long-term animal and
human studies all support that glucose intolerance associated with CLA is an initial response to
CLA supplementation, however, there have been no reports of adverse effects of CLA on glucose
homeostasis in long-term human studies longer than 6 months.99,100,107,127
Along with glucose intolerance, we observed enlarged liver due to CLA treatment in the
current study, which is consistent with other animal studies.17,18,63 It has been suggested that
increased liver weight by CLA may be due to tremendous effects of CLA on fat mobilization
from adipose tissue and increased hepatic lipogenesis, however, no human studies reported any
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changes in markers of liver functions associated with CLA supplementation. Thus, this may be a
species-specific response to CLA.13,269-271
In conclusion, we demonstrated that CLA treatment prevents body weight gain and fat
accumulation by increased physical activity in genetically obese N2KO mice. CLA
supplementation improved voluntary movement and increased skeletal muscle mass, implying
enhanced muscle metabolism through stimulating mitochondrial biogenesis signaling. Although
the precise mechanism underlying the stimulation of mitochondria-related molecular markers is
not clearly elucidated, it is suggested that CLA exerts its action via the activation of PGC-1α
through AMPKα phosphorylation, resulting in mitochondriogenic process through regulating
PGC-1α-PPARδ and/or -Tfam signaling cascades in skeletal muscle. This study provides novel
insights into the preventive effects of CLA on adult-onset inactivity induced obesity by
stimulation of muscle metabolism.
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CHAPTER 6
EFFECTS OF POST-WEANING ADMINISTRATION OF CONJUGATED
LINOLEIC ACID (CLA) ON DEVELOPMENT OF OBESITY IN NESCIENT
HELIX-LOOP-HELIX 2 KNOCKOUT MICE

6.1 Introduction
Since 1980, the prevalence of childhood obesity has almost tripled.272,273 Along with
overnutrition, lack of physical activity during childhood period is one of the significant
contributing factors to development of childhood obesity. Similar to adult obesity, childhood
obesity is known to be associated with the increased risk of chronic metabolism diseases.274,275
Even though early childhood has been considered to be critical for health later in life, most
studies in humans and animals mainly addressed the effects of dietary and exercise regimens
rather than focusing on early-onset interventions during critical developmental periods.276
Conjugated linoleic acid (CLA) is a term describing a mixture of 18-carbon unsaturated
fatty acid isomers with conjugated double bonds. The name, CLA, was first used when its
anticancer activities were reported in 1987.277 Since then, other biological activities of CLA have
been reported, including its effects on prevention of atherosclerosis development, modulation of
immune responses, promotion of young animal growth, and modulation of body composition,
particularly reduction of body fat and improvement of lean and bone masses.14 It has been
suggested that CLA reduces body fat by multiple biochemical mechanisms, including increased
energy expenditure, modulated adipogenesis, and/or enhanced fatty acid β-oxidation.14,15
The beneficial effects of CLA supplementation during the obesity onset period in nescient
basic helix-loop-helix 2 (Nhlh2) knock-out mice (N2KO) have been previously reported.205
Targeted deletion of the Nhlh2 transcription factor expressed in the hypothalamus precedes adultonset obesity in mice, resulting from a disruption of the hypothalamic-pituitary axis. While
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N2KO mice have normal levels of food intake, their spontaneous voluntary movement is
decreased by more than 50% in both genders.247 It was suggested that CLA supplementation in
young N2KO animals prevented excessive weight gain by improving voluntary activity.205
However, it is not clear if supplementation of CLA during pre-obesity stage would benefit later in
life as it was reported in non-obese animals.31 Thus the purpose of this study was to determine the
effects of CLA supplementation during the early growth period in N2KO animals on
development of obesity and symptoms of type 2 diabetes later in life.

6.2 Materials and Methods
6.2.1 Materials
CLA was provided by the Natural Lipids Ltd. AS (Hovdebygda, Norway). The CLA
used consisted of 80.7% CLA (37.8% cis-9,trans-11, 37.6% trans-10,cis-12 and 5.3% other CLA
isomers) and 13.7% oleic acid, 3.2% stearic acid, 0.4% palmitic acid, 0.2% linoleic acid and 1.8%
unknown. Semi-purified powdered diet (TD07518) was obtained from Harlan Laboratories
(Madison, WI). Serum triacylglyceride (TG), glucose, and total cholesterol assay kits were
purchased from Genzyme Diagnostics (Charlottetown, PE, Canada). DC protein assay kit (BioRad, Hercules, CA) was used for protein quantitation. Rabbit antibodies for phosphorylated
AMP-activated protein kinase α (p-AMPKα), AMPKα, phosphorylated phosphatase and tensin
homolog (p-PTEN), phosphorylated phosphoinositide-dependent kinase (p-PDK), phosphorylated
protein kinase B at threonine 308 (p-Akt Thr308) and serine 473 (p-Akt Ser473), Akt and
superoxide dismutase 2 (SOD2) were obtained from Cell Signaling (Berberly, MA). Rabbit
antibodies for peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α), sirtuin 1
(SIRT1), peroxisome proliferator-activated receptor-δ (PPARδ), nuclear respiratory factor 1
(NRF-1), mitochondrial transcription factor A (Tfam), cytochrome c (Cyt C), cytochrome c
oxidase (COX IV), insulin receptor substrate 1 (IRS-1), glucose transporter type 4 (GLUT4) and
β-actin were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Horseradish
64

peroxidase-conjugated goat anti-rabbit IgG antibody was from Boston Bioproducts Inc. (Ashland,
MA). Other chemicals used were purchased from either Sigma Chemical Co. (St. Louis, MO) or
Fisher Scientific (Pittsburg, PA).

6.2.2 Animals and Diets
All animal work was conducted in compliance with the Institutional Animal Care and Use
Committee at the University of Massachusetts. As described in a previous report,247 129Sv/J male
offspring mice were obtained through inbreeding between heterozygous male and female
breeders. Litters were housed together with dams until weaning. At 3-week-old, all male mice
were biopsied (0.5-cm tail) for genotyping. Ten wild type and eight male N2KO mice were
selected for this study, and then placed in individual wire-bottomed cages on a 12:12 h light:dark
cycle in a temperature and humidity controlled room. During a 1-week acclimatization period, all
mice were fed a semi-purified powdered control diet (20 w/w% fat) to induce obesity in rodents
63,205,278

and were subjected to baseline test for voluntary movement and glucose tolerance in

serum. Based on body weight, all animals in different genotype groups (wild type and N2KO)
were divided into two diet groups and fed either control or 0.5% CLA containing diet for 4
weeks. Then, all animals received the control diet for 8 weeks. Previously it was determined that
feeding CLA for 4 weeks in mice was enough to result in changes of body composition as well as
changes in activity levels.17,30 Moreover, it was reported that most CLA remaining in the tissues
(liver, adipose tissue and muscle) returned to comparable levels to control animals at 8 weeks
post withdrawal.30 Thus we selected 8 weeks post CLA supplementation in the current study.
Dose of CLA was determined based on previous reports that supplementing 0.5% CLA for 2-4
weeks in rats led to serum level range of 23 to 120 µM and serum levels of CLA after
supplementation of 0.8-3.2 g per day for 2 months in humans ranged from 23 to 200 µM.27,226
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The compositions of diets are shown in Table 6.1. Diet and water were available ad libitum
throughout the experiment and provided freshly twice per week. Body weight and food intake
were monitored weekly. At the end of the study, mice were fasted for 6 h and sacrificed by CO2
asphyxiation. Blood was immediately collected by cardiac puncture, and internal organs (liver,
heart, kidney, spleen, white adipose tissues including epididymal, retroperitoneal and mesenteric
fat pads) were weighed at sacrifice.
Table 6.1. Composition of experimental diet for control and conjugated linoleic acid (CLA) groups.
Ingredient

g/kg

Casein, ‘vitamin-free’ tested

169.1

L-Cystine

2.2

Sucrose

100

Cornstarch

288.5

Maltodextrin

132

Cellulose

50

Soybean oil

195

CLA or Soybean oil

5

Mineral mix, AIN-93M-MX (TD 94049)

42.8

Vitamin mix, AIN-93-VX (TD 94047)

12.4

Choline bitartrate

3

tert-Butylhydroquinone

0.04

Total

1,000

6.2.3 Voluntary movement measurement (Non-exercise physical activity test)
Non-exercise physical activity (voluntary movement) was recorded using LoliTrack
Quatro Video Tracking Software Version 1.0 (Loligo Systems, Tjele, Denmark) with a highresolution camera under dark condition. This tracking system simultaneously monitored four
mice placed in individual cages (30 × 46 × 40 cm) during the dark phase (5:00pm-5:00am) once a
month with free access to diet and water (provided as HydroGel, Clear H2O, Portland, ME).
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Movement data for 8 h (7:00pm-3:00am) excluding for the first 2 h (5:00pm-7:00pm) during
early phase for adapting to environmental change and 2 h (3:00am-5:00am) during late phase due
to lack of movement were analyzed.

6.2.4 Serum Parameters
The levels of glucose, total cholesterol and TG in serum separated by centrifugation at
3,000 g for 20 min at 4°C were determined using commercial kits as specified by the
manufacturer’s instruction.

6.2.5 Glucose Tolerance Test
As described previously 252, intraperitoneal glucose tolerance tests (IGTT) were
conducted every four weeks. All mice underwent 6 h fasting and then were subjected to baseline
measurement of blood glucose levels at 0 min. Blood was collected from the tail vein using blood
glucose meter, Advocate Redi-Code+ (Advocate Meters Inc., Dorado, Puerto rico). Subsequently,
30% glucose solution (2.0g glucose/kg body weight) was administered through intraperitoneal
injection and then blood glucose levels were monitored at 15, 30, 60, 90 and 120 min. Collected
data were calculated as the areas under the curve (AUC) with SigmaPlot 11.0 (Systat Software,
Inc., San Jose, CA).

6.2.6 Western Blot Analysis
The frozen gastrocnemius skeletal muscle tissue was ground and 50 mg aliquots were
prepared and stored at -80°C until analysis. Each sample was homogenized in premixed lysis
radioimmune precipitation assay (RIPA) (50 mM Tris-HCl, 10 mM NaCl, 5 mM MgCl2, and
0.5% NP-40, pH 8.0) buffer (Boston Bioproducts Inc., Ashland, MA), protease inhibitor cocktail
(Sigma Aldrich, St. Louis, MO) and phosphatase inhibitor cocktail (Thermo Scientific, Rockford,
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IL) and then lysed on ice for 2 h, and centrifuged at 12,000g for 20 min at 4°C. The concentration
of protein from tissue lysate was determined using the DC protein assay kit. The normalized
lysates (37.5 µg/ml protein) were separated by an 8-15% (w/v) sodium dodecyl sulfatepolyacrylamide gel and transferred to a polyvinylidene fluoride membrane (Millipore, Bedford,
MA). After incubating with appropriate primary rabbit antibodies, membranes were treated with
horseradish peroxidase-conjugated goat anti-rabbit IgG antibody for 1 h at room temperature.
Detection was performed using the Enhanced Chemiluminescence solution (Bio-Rad, Hercules,
CA) with an Image Station 4000MM (Carestream Health, New Heaven, CT). The band density
was normalized by β-actin intensity as an internal control. The results were quantified using
Image J software (U.S. National Institutes of Health).

6.2.7 Statistical analyses
All data analyses were performed by two-way analysis of variance (ANOVA) followed
by PROC MIXED procedure with Least Square (LS) Means statement of the SAS software
(Version 9.3, SAS Institute Inc., Cary, NC, USA). For data on body weight, food intake,
voluntary movement and glucose tolerance test, two-way repeated measures ANOVA and the
slice option in the LS means statement to examine the group differences at each time point with
PROC MIXED were used. For internal organ, adipose tissue weight and serum parameters data,
two-way ANOVA with PROC MIXED were conducted. The experimental groups were compared
by the multiple comparisons basically Tukey-Kramer’ method in SAS. Dunnett’s test in SAS was
used for the relative protein expression level. Data are shown as the mean ± S.E. P values less
than 0.05 are reported as statistically significant.
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6.3 Results
6.3.1 Body Weights and Food Intake
There was significant genotype effect on weight gain; N2KO mice significantly had
greater body weight gain over wild type mice (P = 0.0001, Fig. 6.1A). CLA supplementation
during first 4 weeks resulted in no significant different effects on weight gain overall, although
wild type CLA-fed group had the least body weight gain among all treatment groups during the
whole experimental period (Fig. 6.1A).

Figure 6.1 Effect of post-weaning administration of conjugated linoleic acid (CLA) on body
weight (A) and food intake (B) in wild type and N2KO mice.

Overall N2KO mice consumed more food than wild type animals during the
experimental period (P = 0.0252). No significant differences in food intake were observed
between controls and CLA treatment during pre-obese period, although N2KO CLA group
temporarily consumed more food right after withdrawal of CLA supplementation for 2 weeks
(N2KO control; 50.5 ± 5.6 g vs N2KO CLA; 63.0 ± 2.3 g, the mean ± S.E.). Although three-way
interaction among genotype, CLA and time was observed, there was no significant two-way
interaction in food intake (Fig. 6.1B).
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6.3.2 Tissue and Organ Weights
Total adipose tissue weight including epididymal, mesenteric, and retroperitoneal
adipose tissue and internal organ weights (liver, heart, kidney and spleen) are shown in Table 6.2.
Epididymal, mesenteric and total adipose tissue weights were significantly increased in N2KO
animals compared to wild-types (all P values were less than 0.05), but no significant effects of
genotypes was observed for retroperitoneal fat weights. No significant effects of CLA
supplementation for first 4 weeks were observed for adipose tissue weights.
No differences of genotype effects were observed in the liver, heart and spleen weights,
while significant genotype effects were observed for the kidney weights (P = 0.0261). CLA-fed
animals had significantly increased liver, heart and kidney weights compared to control animals.
No significant interaction between genotypes and CLA was observed in all tissue and organ
weights.

Table 6.2. Effects of post-weaning administration of conjugated linoleic acid (CLA) on organ
weights in wild and N2KO mice.

Values represent means ± S.E. (n = 3-5). a-cMeans with different superscripts within the same row are
significantly different (P < 0.05). P-values in table are from two-way ANOVA. N2KO, nescient helix-loophelix knock-out mice; CLA, conjugated linoleic acid; n.s., not significant.
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6.3.3 Voluntary Movement Measurement (Non-exercise Physical Activity Test)
To evaluate the effects of post-weaning administration of CLA on physical activity,
voluntary movement (non-exercise physical activity) was measured every four weeks. Travel
distance as total (19:00-03:00), and two time periods, early (19:00-23:00) and late (23:00-03:00)
were shown in Fig. 6.2A-C. The changes of total travel distance over time were shown in Fig.
6.2D.

Figure 6.2 Effect of post-weaning conjugated linoleic acid (CLA) treatment on voluntary
movement (non-exercise physical activity) in wild type and N2KO mice.
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Consistent with the previous reports,205,253 N2KO mice showed significant decreasing
tendency of activity compared to wild type animals (P = 0.0492). It was evident that all
experimental groups except wild type CLA group showed declining activity over time (Fig.
6.2D), with overall CLA effects significant (P = 0.0444), particularly during the late period (P =
0.0234). No difference in activity between N2KO groups was observed, while CLA fed wild
types, but not N2KO animals, maintained activity levels throughout experimental. This suggests
that supplementation of CLA during pre-obese state prevented reduction of voluntary movement
over time in wild types but not in N2KO animals.

6.3.4 Glucose Tolerance Test
To determine the effects of post-weaning CLA treatment on glucose homeostasis,
glucose tolerance tests were conducted every four weeks (Fig. 6.3A-D). N2KO mice showed
glucose intolerance compared to wild type animals (P = 0.0061). In addition, there was
significant overall time effect (P = 0.0148), suggesting these animals develop glucose intolerance
with ageing along with high-fat diet as used in this study. No significant CLA effect was
observed, however, the CLA treated wild type animals improved glucose tolerance at week 12
compared to wild-type controls, even after CLA withdrawal for 8 weeks (Fig. 6.3E, P<0.0001 for
the interaction effect between CLA and time). This suggests that post-weaning CLA
administration may improve glucose tolerance in wild-types but not in N2KOs.

6.3.5 Serum Parameters
The serum levels of TG, glucose, and total cholesterol were analyzed and shown in
Table 6.3. There were no genotype or CLA effect on these markers in this study, except glucose
levels for CLA (P = 0.036). No interaction between genotype and CLA were observed in all of
these parameters.
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Figure 6.3 Effect of time-specific post-weaning conjugated linoleic acid (CLA) treatment on
glucose levels (A-D), the area under the curve (AUC) change (E) and overall trend of AUC
change (F) in wild type and N2KO mice.

6.3.6 Effects on Muscle Metabolism
To assess whether post-weaning administration of CLA attributes to improved skeletal
muscle energy metabolism, we investigated the AMPK signaling pathway, a master sensor to
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Table 6.3. Effects of post-weaning administration of conjugated linoleic acid (CLA) on serum
parameters in wild and N2KO mice.

Values represent means ± S.E. (n = 3-5). P-values in table are from two-way ANOVA. N2KO, nescient
helix-loop-helix knock-out mice; CLA, conjugated linoleic acid; n.s., not significant.

Table 6.3. Serum parameters maintain energy homeostasis (Fig. 6.4). Total AMPKα was
measured, as it is known that two subunits (α1 and α2) are regulated differentially and overall
AMPKα activity is more important.279 There were no overall effects of any genotype or CLA
effects on AMPKα expression, but interaction between them was observed (P = 0.0471) (Fig.
6.4B). For phosphorylated AMPKα (the active form of AMPKα), N2KO animals had
significantly lower levels of p-AMPKα compared to wild type (P = 0.0399). The mice
supplemented CLA for the first 4 weeks showed significantly higher expression of
phosphorylation of AMPKα over the control groups (Fig. 6.4C, P = 0.0264), particularly wild
type CLA group compared to the respective control (Fig. 6.4C). In addition, increased ratio of
phosphorylated AMPKα to AMPKα by CLA was observed (Fig. 6.4D, P = 0.0471).
Along with AMPKα, SIRT1 (a NAD-dependent deacetylase) is a key activator of PGC1α (one major downstream marker for AMPKα). There were no significant effects of genotype
and CLA on SIRT1 observed, whereas wild type CLA group showed increased SIRT1 expression
level over N2KO control (Fig. 6.4E). The expression of PGC-1α, a master regulator of
mitochondrial biogenesis, was not influenced by genotype or CLA either (Fig. 6.4F). However, it
was evident that CLA treatment had greater effect on PGC-1α than control diet group in wild type
animals.
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Figure 6.4 Effect of post-weaning treatment of conjugated linoleic acid (CLA) on protein
expression of total and phosphorylated AMP-activated protein kinase (AMPK), SIRT1, and PGC1α from the gastrocnemius muscle in wild type and N2KO mice.

6.3.7 Effects on Mitochondrial Biogenesis-related Factors
We further determined the effect of post-weaning CLA supplementation on
mitochondrial biogenesis in the gastrocnemius muscle. Mitochondria are the important organelle
to determine the oxidative capacity and fatigue resistance, resulting in prolonged endurance
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capacity.249,280,281 For mitochondrial biogenesis several nuclear encoded precursor proteins are
involved in this metabolic process10,230,282, among them we selected PPARδ, NRF-1 and Tfam.
PPARδ is a marker involved in mitochondrial biogenesis as well as muscle type
transformation from glycolytic to oxidative fiber.192 No significant overall effects of genotypes or
CLA were observed on PPARδ, however, wild type CLA-fed animals showed significantly
greater expression levels of effect of PPARδ compared to both control diet groups (Fig. 6.5B). No
significant difference in NRF-1, a regulator to mediate nuclear-encoding mitochondrial proteins,
was observed in all experimental groups (Fig. 6.5C). The expression of Tfam, which is the key
regulator for mitochondrial DNA replication and transcription, was significantly down-regulated
in N2KO mice over wild type mice (P = 0.0062). The CLA supplemented group in wild type
animals showed significantly greater Tfam expression over control group in N2KO mice (Fig.
6.5D).

Figure 6.5 Effect of post-weaning treatment of conjugated linoleic acid (CLA) on mitochondrial
biogenesis-related factors from the gastrocnemius muscle in wild type and N2KO mice.
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To estimate overall mitochondrial relative content we used an indirect method to
measure mitochondrial proteins including cytochrome c and COX IV located in the inner
membrane of mitochondria.228,232 Additionally, we tested another mitochondrial protein,
superoxide dismutase 2 (SOD2) in the inner mitochondrial matrix, to assess mitochondrial
function.234 The expression levels of cytochrome c were significantly decreased in N2KO mice
compared to wild type animals (P = 0.0496) but no CLA effects were observed (Fig. 6.6B). No
genotype or CLA effects were observed in COX IV (Fig. 6.6C). Overall SOD2 protein levels
were significantly reduced in N2KO mice (P = 0.0224), while no effects of CLA were observed
(Fig. 6.6D).

Figure 6.6 Effect of post-weaning treatment of conjugated linoleic acid (CLA) on mitochondrial
content and function from the gastrocnemius muscle in wild type and N2KO mice.
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6.3.8 Effects on Markers of Glucose Metabolism
Along with assessment of post-weaning administration of CLA on mitochondrial biogenesisrelated factors, we determined the effects of CLA supplementation during first 4 weeks on
markers of glucose metabolism in the gastrocnemius muscle. The expression levels of IRS-1, a
member of IRS family regulating insulin signaling, were significantly decreased in N2KO
animals over wild types, while no CLA effects were observed (Fig. 6.7B, overall genotype effect,
P = 0.0335).
A downstream biomarker of IRS (PTEN, attributed to negatively regulate the AKT signaling
pathway) significantly reduced phosphorylation (inactive form of PTEN) in N2KO mice
compared to wild type animals (P = 0.0094). No significant effect of post-weaning administration
of CLA was observed on PTEN expression. However, CLA-treated wild type animals
significantly upregulated phosphorylated PTEN compared to the respective control, while no
differences were observed in N2KO animals (Fig. 6.7C).
No difference in protein expression of phosphorylated PDK, a downstream marker of
PTEN, was observed for both genotype and CLA (Fig. 6.7C). There were no significant effects of
genotypes and CLA in total AKT expressions and phosphorylated AKT (Serine 473) and GLUT4,
one of the insulin-regulated glucose transporters (Fig. 6.7D-G). However, we observed
marginally increased responses from wild type animals fed CLA on phosphorylated AKT
(Threonine 308) compared to the respective control (P = 0.0547 and P = 0.0528, respectively).

6.4 Discussion
It was previously reported that supplementation of CLA prevents weight gain and body
fat accumulation during both the growth period and in aged N2KO mice.57,205,283 Particularly,
CLA increased voluntary activity when supplemented during growth period.205,283 Results from
the current study suggest that supplementation of CLA in pre-obese state may reduce weight gain
in normal animals but not in the genetically induced inactive adult-onset animal model, although
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Figure 6.7 Effect of post-weaning treatment of conjugated linoleic acid (CLA) on glucose
metabolism from the gastrocnemius muscle in wild type and N2KO mice.

the stimulation of voluntary activity and improved glucose tolerance remain even after CLA
withdrawal in this model.
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Previously CLA was reported to be linked with reduced food intake in a number of
animal models, although it was not consistent.28-30,71 Moreover, it was determined that the
reduction of food intake by CLA was independent of its effects on body fat reduction.28,30 Others
suggested that CLA reduces food intake by decreasing neuropeptides Y (NPY) and agouti-related
protein (AgRP), both of which are known to be related to increased appetite 284 and inducing the
storage of glycogen in muscle and liver, which may subsequently serve as satiety signals.285,286 In
the current study, we did not observe any significant differences in food intake during CLA
supplementation periods in both genotypes. However, when CLA was withdrawn, apparent
compensation of food intake occurred in N2KO animals fed CLA, but not in wild type animals,
coincided with greater weight gain during this period (Week 4-6 in Fig. 6.1A). It is not clear how
CLA influenced food intake in these animals, however, these results suggest that CLA may
influence food intake differently in obese animals, which has been previously reported in other
animal models.28,30,32,71
We observed that N2KO mice had significantly reduced physical activity consistent with
previous reports for N2KO animals.205,247,248 Overall, post-weaning CLA supplementation
significantly prevented reduction of voluntary activity levels compared to controls, particularly in
wild type animals. Intriguingly, our results showed that the effects of CLA on activity during the
late phase (23:00-03:00) might remain even after termination of CLA treatment up to 8 weeks,
whereas during the early phase (19:00-23:00) there was no significant CLA effect in all
experimental groups.
Among various molecular mechanisms to affect increased or maintained physical
activity levels, AMPK signaling pathway has drawn significant attention since the 1990s.183
Upregulated AMPK signaling pathway is involved in skeletal muscle energy metabolism as well
as mitochondrial biogenesis, resulting in enhanced endurance capacity and attenuated exercise
intolerance.3-5,287 Previously, our group demonstrated the effect of CLA on stimulation of
mitochondrial biogenesis through AMPK signaling pathway.250 In the same context, our data
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supported post-weaning administration of CLA might stimulate activation of AMPKα and related
factors in wild type but not in N2KO animals.
Wild type animals fed CLA for first 4 weeks showed improved glucose tolerance over
time even after no benefits on weight were observed compared to respective control, suggesting
CLA may have lasting effects on glucose metabolism later in life. Based on this observation, we
assessed effects of CLA treatment during growth period on glucose metabolism through insulin
signaling pathway. Among several measured markers involved in insulin signaling cascades,
phosphorylated PTEN and phosphorylated AKT at threonine 308 partially provided evidence
regarding how to moderate glucose tolerance in the current study. PTEN and AKT are important
effectors of insulin responses mediating glucose uptake and glycogen synthesis in skeletal
muscle.288-291 Our data are consistent with early studies that CLA specific isomers mediate AKT
sensitization.194,196
Current the results suggest potential benefits of post-weaning CLA administration to
reduce health risk, as suggested previously.253,283 This is important since one potential health
concern associated with CLA supplementation is glucose intolerance. We observed a nonsignificant increase in glucose intolerance following CLA supplementation in wild type mice
(Fig. 6.3B, week 4), however, when CLA was withdrawn, glucose tolerance improved in the
treated groups (week 12 in Fig. 6.3D). As suggested before, this may be due in part to significant
shift of energy metabolism by CLA, such as increased fatty acid β-oxidation associated with
reduced glucose utilization.265,268 However, further studies such as HOMA-IR to better understand
glucose and insulin metabolism are needed to determine how post-weaning administration of
CLA changes energy sources.
As seen in previous studies,17,18,152 we observed a significant increase in liver weight, as
fatty liver, after CLA supplementation. It is unlikely that CLA is directly accumulated in the liver
as levels of CLA in the liver and muscle reached maximum 1 week for liver and 2 weeks for
muscle after supplementation in mice.292 Previously it was reported that CLA fed animals
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accumulate TG in the liver.293,294 It is believed to be associated with CLA’s dramatic effects on
lipid metabolism, particularly in the liver and adipose tissues, increased hepatic lipogenesis and
decreased fat accumulation in adipose tissues.13,15,270,271 It is unlikely that enlarged liver caused by
CLA is due to increased glycogen content as it was previously shown that CLA had no effects on
enzyme activities involved in gluconeogenesis.292 In addition, previous studies reported no
pathologically significant observations after 18 months CLA supplementation or no changes in
hepatic gene expressions in lipogenesis from N2KO animals.57,205,295 Although we provided CLA
during pre-obese state only and then withdrew CLA, the significant effect of CLA on liver weight
still remains. This is consistent with the previous study that withdrawal of CLA did not
completely reverse liver enlargement at the end of a 4 week recovery period.269 Our study might
not have enough adaptive time to complete this reversal of CLA’s effect. Thus, additional
investigation of relationship between short-term CLA supplementation and changes in hepatic
genes should be considered to determine if the liver enlargement caused by CLA is completely
reversible or not. Clinical trials with CLA reported no changes or increased markers for liver
function, and all were within the normal ranges. In addition, it was reported that a high-dose of
CLA (14.6 g cis-9,trans-11 and 4.7g trans-10,cis-12 CLA per day) for 3 weeks had no changes
on markers of liver function in healthy subjects. Thus, it is possible that rodents are more
sensitive to CLA’s effect compared than humans.
In conclusion, CLA supplementation during pre-obese state may attenuate reduction of voluntary
activity and glucose intolerance after CLA withdrawal in this mouse model. However, it is not
sufficient per se to maintain health benefits like prevention of weight gain and fat accumulation
until later life in genetically obese mice. Wild type animals fed CLA may activate AMPKα and
PPARδ as well as promote desensitization of PTEN and sensitization of AKT at threonine 308 in
gastrocnemius skeletal muscle, improving voluntary activity and glucose homeostasis. We
suggest that post-weaning administration of CLA may partially stimulate the underlying
molecular targets involved in muscle energy metabolism in normal animals but not in the
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genetically induced inactive adult-onset animal model. The present study would provide a
scientific foundation for future trials of targeted application of post-weaning CLA intervention in
modulating long-term obesity. If further research on genetically predisposed obese mice
discovered an appropriate intervention or combination with an addition regime like exercise, it
may be possible to more effectively be used to prevent childhood obesity.
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CHAPTER 7
CONJUGATED LINOLEIC ACID (CLA) PROMOTES ENDURANCE
CAPACITY VIA PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR
(PPAR) δ-MEDIATED METABOLISM IN MICE

7.1 Introduction
There are two distinct types of exercise training: strength and endurance. Strength
exercises such as weightlifting and bodybuilding promote protein synthesis and then induce
hypertrophy of muscle cells. On the other hand, endurance exercises including jogging,
swimming and cycling stimulate mitochondrial biogenesis and then contribute to decreased
incidences of obesity through enhanced energy expenditure and switching the energy source from
glucose to fat 296. Also, chronic endurance training triggers a remodeling of the skeletal muscle
fiber phenotype from type II (glycolytic fast-twitch fibers) to type I (oxidative slow-twitch
fibers). In general, type I fibers in skeletal muscle have a greater density of mitochondria than
type II fibers. Thus, oxidative type I fibers promotes fatty acid β-oxidation to spend the stored fat
in the body 297. As a consequence, it induces body fat reduction, leading to the prevention of
obesity.
It is known that mitochondrial biogenesis and a shift of fiber type composition are major
metabolic events that influence endurance exercise training, and vice versa 296. The primary
biomarkers implicated in mitochondrial biogenesis and fiber type transformation in skeletal
muscle are peroxisome proliferator-activated receptor δ (PPARδ) and PPARγ coactivator 1α
(PGC-1α) 257. Although it is well established that PGC-1α acts as a master regulator in
mitochondrial biogenesis, mice that ectopically overexpressed PGC-1α showed a remarkable
conversion of muscle fiber type II to type I. Likewise, muscle specific overexpression of PPARδ
in mice simultaneously increased the number of copies of mitochondrial DNA and up-regulated
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the expression levels of mitochondrial biogenesis-related genes, inducing a shift of skeletal
muscle fibers from type II to type I 192.
During the last two decades conjugated linoleic acid (CLA) has gained significant attention
as a bioactive compound to prevent obesity. Although most of CLA’s anti-obesity effects have
been focused on body fat reduction, accumulated evidence demonstrated that CLA increased lean
body mass and enhanced physical performances 14,120. In fact, the previous studies in rodents
reported that CLA improved voluntary activity and endurance capacity through the modulation of
molecular targets such as carnitine palmitoyltransferase 1 (CPT1), uncoupling protein 2 (UCP2)
and peroxisome proliferator-activated receptor δ (PPARδ) in skeletal muscle 17,18. Recently, it was
revealed that the specific CLA isomers, cis-9,trans-11 and trans-10,cis-12, induced the upregulation of key molecular markers involved in mitochondrial biogenesis 250. This evidence
provides the opportunity for future studies to investigate the effects of CLA on skeletal muscle
metabolism. Thus, we investigated the regulating mechanisms of CLA in skeletal muscle to elicit
the effects of CLA on endurance capacity in mice, and to clarify the interaction of CLA and
exercise based on PPARδ-mediated metabolism.

7.2 Materials and methods
7.2.1 Materials
CLA was provided by Natural Lipids Ltd. AS (Hovdebygda, Norway). The purity of
CLA was 80.7% (37.8% cis-9,trans-11, 37.6% trans-10,cis-12 and 5.3% other CLA isomers and
the remainder of the preparation was 13.7% oleic acid, 3.2% stearic acid, 0.4% palmitic acid,
0.2% linoleic acid and 1.8% was unknown). Semi-purified powdered diets (TD07518, 95% basal
mix) were obtained from Harlan Laboratories (Madison, WI). Serum triacylglyceride (TG),
glucose, and total cholesterol assay kits were purchased from Genzyme Diagnostics
(Charlottetown, PE, Canada). Serum non-esterified fatty acids (NEFA) and L-Lactate were
obtained from BioAssay Systems (Hayward, CA). The blood urine nitrogen (BUN) assay kit was
85

purchased from BioQuant (San Diege, CA). DC protein assay kits for analysis of protein
concentration were from Bio-Rad (Hercules, CA). Rabbit antibodies for phosphorylated AMPactivated protein kinase α (p-AMPKα), AMPKα, phosphorylated phosphatase and superoxide
dismutase 2 (SOD2) were obtained from Cell Signaling (Berberly, MA). Rabbit antibodies for
PGC-1α, sirtuin 1 (SIRT1), PPAR, nuclear respiratory factor 1 (NRF-1), mitochondrial
transcription factor A (Tfam), cytochrome c (Cyt C) and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA). Horseradish peroxidase-conjugated goat anti-rabbit IgG antibody was from Boston
Bioproducts Inc. (Ashland, MA). Other chemicals used were purchased from either Sigma
Chemical Co. (St. Louis, MO) or Fisher Scientific (Pittsburg, PA).

7.2.2 Animals and diet
All work related to animals was done in compliance with the Institutional Animal Care
and Use Committee at the University of Massachusetts, Amherst. Twenty 10-week-old male
129Sv/J mice were obtained from breeding colonies. All mice were placed in individual wirebottom cages with 12h light and dark cycles in a temperature and humidity-controlled room. All
mice underwent a 1-week acclimatization period. During that period, a control powder diet with
40% calories from fat was provided to all mice. They were subjected to baseline testing for
endurance capacity and voluntary activity. All mice were divided into four different groups
according to diet and exercise regimes, either as control or 0.5% CLA with high-fat (40% fat
calorie) diets, as well as sedentary or exercise groups. The dose of CLA used for the current study
was determined on the basis of previous reports in rats and humans. In rats, 0.5% CLA
supplementation for 2−4 weeks caused a range between 23−120 µM in serum and 0.8−3.2 g per
day supplemented with CLA for 2 months in humans led to serum levels from 23 to 200 µM 27,226.
The formulation of diets was shown in Table 7.1. The duration of this study was four weeks.
Body weight and food intake were recorded once a week. After a four-week intervention, the
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mice fasted for 4 h, exercised for 15 min, run the same way as the training protocol, and then
sacrificed by CO2 asphyxiation. For analysis of serum markers, blood was collected using the
cardiac puncture method. Three different parts of adipose tissue (epididymal, retroperitoneal and
mesenteric), two designated parts of skeletal muscle (gastrocnemius and quadriceps) and other
organs (liver, heart, kidney and spleen) were harvested and weighed.

Table 7.1. Composition of experimental diet for control and conjugated linoleic acid (CLA) groups.
Ingredient

g/kg

Casein, ‘vitamin-free’ tested

169.1

L-Cystine

2.2

Sucrose

100

Cornstarch

288.5

Maltodextrin

132

Cellulose

50

Soybean oil

195

CLA or Soybean oil

5

Mineral mix, AIN-93M-MX (TD 94049)

42.8

Vitamin mix, AIN-93-VX (TD 94047)

12.4

Choline bitartrate

3

tert-Butylhydroquinone

0.04

Total

1,000

7.2.3 Endurance capacity test
All mice were subjected to running training on the treadmill (Columbus Instrument,
Columbus, OH) during the acclimatization period (week 0). The protocol of adaptation placed all
mice on the treadmill to run for 15 min with a speed of 10 m/min on a 0° incline under the control
of an electric shock grid. This training for adaptation was repeated three times and then all mice
were measured on a baseline of endurance capacity, for a total running time (min) and distance
(m) at the end of the adaptation period.
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During the whole experimental period, mice in the exercise groups trained with running
exercises five times a week on the motorized treadmill. The detailed endurance training protocol
performed running training for a total of 15 min (10 m/min for the first 10 min, then an increase
of 1 m/min every minute for the following 5 min, with a final speed of 15 m/min for training) on
a 10° inclination with an electric shock grid (0.97 mA) to encourage continuous running.
Endurance capacity was evaluated biweekly. The testing protocol used the same initial
conditions as the training protocol (10 m/min on 10° inclination), however, the speed was
increased by 1 m/min every minute until reaching 25 m/min, and the speed of 25 m/min was
maintained until they were fatigued or exhausted. Exhausted means mice stay on the electric
shock grid for five continuous seconds or for three times over two seconds 298,299. The total
running time and distance determined that these variables were representative markers to reflect
endurance capacity.

7.2.4 Voluntary movement measurement (Non-exercise physical activity test)
Voluntary movement was recorded using LoliTrack Quatro Video Tracking Software
Version 1.0 (Loligo Systems, Tjele, Denmark) with a high-resolution infrared camera during the
dark cycle (5:00pm-5:00am) every other week. Animals were individually placed into cages with
free access to diet and water (provided as HydroGel, Clear H2O, Portland, ME). The cage (30 ×
46 × 40 cm) used for activity monitoring was larger than the typical cage to avoid limited
voluntary movements. Among the monitored movement data for 12 h (5:00pm-5:00am), and 8 h
(7:00pm-3:00am) were analyzed with the exception of the first 2 h (5:00pm-7:00pm) and 2 h
(3:00am-5:00am) due to early adaption and a lack of movement, respectively.

7.2.5 Serum parameters
The levels of glucose, total cholesterol, TG, NEFA, BUN and L-Lactate in serum were
separated by centrifugation at 3,000 g for 20 min at 4°C and were subsequently measured using
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commercial kits.

7.2.6 Western blot analysis
Each sample from gastrocnemius muscle tissue was homogenized in radioimmune
precipitation assay (RIPA) (50 mM Tris-HCl, 10 mM NaCl, 5 mM MgCl2, and 0.5% NP-40, pH
8.0) buffer (Boston Bioproducts Inc., Ashland, MA), protease inhibitor cocktail (Sigma Aldrich,
St. Louis, MO) and a phosphatase inhibitor cocktail (Thermo Scientific, Rockford, IL) and was
lysed on ice for 2 h with gentle shaking, then centrifuged at 14,000g for 20 min at 4°C. The
protein concentration in tissue lysate was normalized at 50 µg/ml of protein. The normalized
samples were mixed with loading buffer, and then separated by a 10-15% (w/v) sodium dodecyl
sulfate-polyacrylamide gel and were transferred onto a polyvinylidene fluoride membrane
(Millipore, Bedford, MA). After blocking, proteins were probed with primary rabbit antibodies,
and were then incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG antibody
for 1 h at room temperature. For detection, the Enhanced Chemiluminescence solution (Bio-Rad,
Hercules, CA) was used and developed under the Image Station 4000MM (Carestream Health,
New Heaven, CT) setting. GAPDH was used as a loading control for normalization. The results
were quantified using Image J software (U.S. National Institutes of Health).

7.2.7 mRNA analysis
Total RNA was isolated from the gastrocnemius muscle tissue (50 mg) in TRIzol
reagent (Invitrogen, Calsbad, CA), and was then reversely transcribed to cDNA using a High
Capacity cDNA Reverse Transcription kit (Applied Biosystems, Forster, CA). cDNA with
predesigned TaqMan gene expression assay kits was used for the relative quantitation. The target
genes were lipoprotein lipase (LPL, Mm00434764_m1), fatty acid binding protein 4 (Fabp4,
Mm00445878_m1), PPARα (Mm00440903_m1), CPT1β (Mm00487200_m1) and UCP2
(Mm00627597_m1) for lipid metabolism, and phosphoinositide 3-kinase (PI3K)
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(Mm00803160_m1), pyruvate dehydrogenase kinase, isoform 4 (PDK4, Mm01166879_m1),
protein kinase B1 (AKT1, Mm01331626_m1) and glucose transporter type 4 (GLUT4,
Mm01245502_m1) for glucose metabolism. For analysis of muscle fiber type transformation we
used four target genes, myosin heavy chain 1 (MHC1, Mm01332493_m1), MHC2
(Mm01332564_m1), MHC3 (Mm01332463_m1) and MHC7 (Mm01332518_m1). GAPDH
(Mm99999915_g1) and 18S ribosomal RNA (18S rRNA, Mm03928990_g1) were used for
internal standards. All reactions were triplicated with the StepOnePlus Real-Time PCR System
(Applied Biosystems, Foster, CA). The program of reaction was 2 min at 50°C and 10 min at
95°C, followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. Data were calculated using 2–∆∆Ct.

7.2.8 Statistical analyses
Data were analyzed by two-way analysis of variance (ANOVA) followed by PROC
MIXED with Least Square (LS) Means options of the SAS software (Version 9.3, SAS Institute
Inc., Cary, NC, USA). For data on body weight, food intake, endurance capacity and voluntary
movement, two-way repeated measure ANOVA and the slice option in the LS means statement
were used to examine the group differences at each time point with PROC MIXED. For internal
organs, adipose and skeletal muscle tissue weight, serum parameters, the relative protein and
mRNA expression level data, two-way ANOVA with PROC MIXED was used. The TukeyKramer’s method in SAS was used for the multiple comparisons among the experimental groups.
Data were shown as the mean ± S.E. P values less than 0.05 are reported as statistically
significant.

7.3 Results
7.3.1 Body weights and food intake
CLA fed mice gained less body weight than control diet groups from week 2, and
maintained this trend throughout the experiment (overall CLA effect, P < 0.0001). Along with
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CLA effects, exercise effects on body weight gain in trained mice were significant (overall
exercise effect, P = 0.0218). No interaction was observed for diets and exercise in body weight
gain (Fig. 7.1A). At week 2, mice supplemented with CLA decreased food intake compared to
control diet groups. However, there was no significant difference in food intake at the end of the
experiment between any of the groups. Overall CLA and time effects influenced food intake (P =
0.0187 and P < 0.0001, respectively) and there was a significant interaction between the two (P =
0.0007). Exercise effect was not observed in food intake (Fig. 7.1B).

Figure 7.1 Effects of conjugated linoleic acid (CLA) on body weight (A) and food intake (B) in
sedentary and exercise-trained mice.

7.3.2 Tissue weights
Total and individual adipose tissue (epididymal, retroperitoneal, and mesenteric adipose
tissue), skeletal muscle (gastrocnemius and quadriceps), liver, heart and spleen weights are shown
in Table 7.2. Overall CLA-fed mice showed significantly less adipose tissue accumulation than
control diet groups, while no exercise effect was observed in adipose tissue weights. The tissue
weights in gastrocnemius muscle were significantly increased by CLA supplementation (P =
0.0035). Particularly, CLA-fed mice in the exercise trained group had the most gastrocnemius
muscle mass. No differences of exercise effect were observed in the liver, heart and spleen
weights, whereas CLA supplementation significantly influenced the liver weight.
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Table 7.2. Effects of conjugated linoleic acid (CLA) on organ weights in sedentary and exercisetrained mice.

Values represent means ± S.E. (n = 5). a-bMeans with different superscripts within the same row are
significantly different (P < 0.05). P-values in table are from two-way ANOVA. CLA, conjugated linoleic
acid; n.s., not significant.

7.3.3 Endurance capacity and voluntary movement (non-exercise physical activity)
To evaluate endurance capacity, we determined the maximum running time and distance
on the motorized treadmill. Animals in the CLA groups significantly improved the maximum
running time and distance over mice in the control diet groups (P = 0.0166 and P = 0.0174,
respectively). Exercise effect failed to reach significant values in endurance capacity. Time effect
influenced running time and distance. On the other hand, no interaction among time, diets and
exercise were observed. The CLA supplementation and exercise-combined group significantly
prolonged the maximum running time (2.4-fold) and distance (3.2-fold) in comparison to the
sedentary control diet group at week 4. Furthermore, CLA-fed mice in the sedentary group also
increased their running time (1.6-fold) and distance (1.9-fold) compared to the sedentary control
diet group at the same time point (Fig. 7.2A and 7.2B). All experimental groups except the
sedentary control group steadily increased the maximum running distance over time (Fig. 7.2C).
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Effects of CLA on non-exercised physical activity were determined by measuring
voluntary movement three times including a baseline test during the entire experimental period
(Fig. 7.2D). Overall CLA and exercise effects did not show differences in voluntary movement,
although CLA-fed animals showed an increase in voluntary movement compared to control dietfed mice within the sedentary groups at week 4 (paired test, P = 0.0157). On the other hand, in the
exercise-trained groups, CLA supplementation led to no significant changes in voluntary
movement in comparison to control diet feeding.

Figure 7.2 Effects of conjugated linoleic acid (CLA) on maximum running time (A), distance (B)
and trend (C), and voluntary movement (D) in sedentary and exercise-trained mice.
7.3.4 Serum parameters
The concentrations of serum metabolic parameters are shown in Table 7.3. The CLA
supplemented animals had significantly lower levels of serum TG than mice in the control diet
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groups (P = 0.0431). No difference of overall CLA and exercise effects were observed for
glucose, total cholesterol, NEFA, BUN and L-Lactate in mice.

Table 7.3. Effects of conjugated linoleic acid (CLA) on serum parameters in sedentary and
exercise-trained mice.

Values represent means ± S.E. (n = 5). P-values in table are from two-way ANOVA. CLA, conjugated
linoleic acid; n.s., not significant; NEFA, non-esterified fatty acid; BUN, blood urea nitrogen.

7.3.5 Effects on biomarkers in skeletal muscle energy metabolism
To determine the effects of CLA and/or exercise on skeletal muscle metabolism, we
investigated the AMPK-related molecular biomarkers in the regulatory pathway for PPARδ on
the basis of the previous study 18,250. There were no significant overall effects of CLA or exercise
on total AMPKα in all treatments (Fig. 7.3B), while phosphorylated AMPKα (the active form of
AMPKα) was significantly up-regulated in the exercise trained mice (P = 0.0342 for overall
exercise effect, Fig. 7.3C). As a consequence, the ratio of phosphorylated AMPKα to AMPKα
was significantly increased in the exercise trained animals (P = 0.0197 for overall exercise effect,
Fig. 7.3D). SIRT1, a NAD-dependent deacetylase cross-talking to AMPK, was significantly
influenced by CLA supplementation (P = 0.0009 for overall CLA effect, Fig. 7.3E). However,
there was no significant effect of exercise in SIRT1 expression. Similarly, the expression of PGC1α showed significant differences in the CLA-fed groups (P = 0.0127 for overall CLA effect), but
not in the exercise trained mice (Fig. 7.3F).
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7.3.6 Effects on biomarkers in mitochondrial biogenesis signaling cascades
On the basis of the evidence that CLA up-regulated SIRT1 and PGC-1α in the CLA-fed
mice in Fig. 7.3, we further studied the effects of CLA and/or exercise on mitochondrial

Figure 7.3. Effects of conjugated linoleic acid (CLA) on protein expression of AMP-activated
protein kinase (AMPK), sirtuin 1 (SIRT1), and peroxisome proliferator-activated receptor γ
coactivator 1 α (PGC-1α) in sedentary and exercise-trained mice.

biogenesis signaling cascades in the gastrocnemius muscle. It is known that endurance exercise
training stimulates mitochondrial biogenesis, resulting in improved oxidative capacity and
reduced muscle fatigue 249. In fact, PGC-1α is a master regulator in mitochondrial biogenesis,
which orchestrates several nuclear encoded proteins. Among them, we primarily investigated
three major molecular biomarkers, PPARδ, NRF-1 and Tfam. In addition, the activities of
mitochondrial proteins, cytochrome c and SOD2, were evaluated for changes of mitochondrial
function by nutritional and physical treatments. Overall CLA effects showed significantly
increased expression levels of PPARδ compared to control-fed animals (P = 0.0051 for overall
CLA effect, Fig. 7.4B), while no exercise effect was observed for PPARδ. The CLA-fed mice
significantly increased NRF-1 activity, a marker that regulates nuclear-encoding mitochondrial
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proteins, in comparison to control-fed animals (P = 0.0016 for overall CLA effect). The
expression levels of Tfam, a major regulator for mitochondrial DNA replication and transcription,
in the CLA supplemented groups were greater than the controls (P = 0.0195 for overall CLA
effect). There were no exercise effects in both activities of NRF-1 and Tfam (Fig. 7.4C and
7.4D).
We further determined expression levels of mitochondrial proteins, cytochrome c which
is located in the inner membrane of mitochondria, and SOD2 which protects mitochondria from
reactive oxygen species. No significant overall effects of CLA or exercise were observed on
cytochrome c and SOD2; however, the exercise trained mice showed marginally increased
expression levels of both proteins, although the results were not significant (Fig. 7.4E and 7.4F).

Figure 7.4. Effects of conjugated linoleic acid (CLA) on mitochondrial biogenesis-related
molecular markers from the gastrocnemius muscle in sedentary and exercise-trained mice.

7.3.7 Effects on muscle fiber type composition
The effects of CLA and/or exercise on changes in the composition of the four different
genes in myosin heavy chain (MYH) were evaluated in the gastrocnemius muscle (Fig. 7.5).
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These myosin heavy chain genes include MYH7 (slow-twitch fiber type I), MYH3 (embryonic
fiber), MYH2 (slow/fast-twitch fiber type IIa) and MYH1 (fast-twitch fiber type IIx/d). The
significant differences in MYH7 (P < 0.0001), MYH3 (P = 0.0019) and MYH1 (P = 0.0041) were
observed in the CLA-fed animals. On the other hand, the exercise trained mice showed
significantly increased gene expression levels of MYH2 (P = 0.0205 for overall exercise effect).
Specifically, the CLA-fed mice in the exercise trained group expressed the most mRNA levels of
MYH7, MYH3 and MYH2 among all experimental groups.

Figure 7.5. Effects of conjugated linoleic acid (CLA) on skeletal muscle fiber type
transformation. Samples were obtained from the gastrocnemius muscle in sedentary and exercisetrained mice.

7.3.8 Effects on lipid and glucose metabolism in skeletal muscle
To determine the effects of CLA and/or exercise on lipid metabolism in skeletal muscle,
the selected genes measured the mRNA levels in the gastrocnemius muscle (Fig. 7.6A). The CLA
supplementation significantly increased the mRNA expression of LPL (the master regulator of
fatty acid uptake, P = 0.00154), PPARα (the key regulator of lipid metabolism, P = 0.00154) and
CPT 1β (the key enzyme of fatty acid β-oxidation, P = 0.039), while no effects of CLA were
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observed on Fabp4 and UCP2 in muscle. Overall exercise effect was not shown in lipid
metabolism.

Figure 7.6. Effects of conjugated linoleic acid (CLA) on mRNA expressions of selected genes
representative to lipid metabolism (A) and glucose and insulin metabolism (B) in the
gastrocnemius muscle in sedentary and exercise-trained mice.

The relative mRNA expression levels of PI3K, PDK4, AKT1 and GLUT4, markers for
glucose and insulin metabolism, were determined in the gastrocnemius muscle (Fig. 7.6B).
Among these targets, mRNA levels of GLUT4 (the insulin-regulated glucose transporter) were
significantly up-regulated by CLA supplementation (P = 0.0447), but not by exercise training.

7.4 Discussion
Previously, numerous studies with CLA investigated the mechanisms to reduce body
weight and body fat mass by modulating metabolism in adipose tissues 15,16. However, the effects
of CLA on skeletal muscle metabolism have garnered relatively less attention, even though a
number of early studies demonstrated that CLA increased lean body mass, including muscle mass
and improved physical activities 120. In the current study, we have assessed the effects of CLA on
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endurance capacity and the metabolic alteration of intracellular molecular markers in skeletal
muscle. Of particular importance, up- and down-stream markers of PPARδ regulated
mitochondrial biogenesis and muscle fiber type composition. Those markers were primarily
investigated as the metabolic events that influence endurance capacity. Results from the present
study indicated that CLA supplementation, but not exercise training, stimulated mitochondrial
biogenesis and induced genes of myosin heavy chains composed of muscle fiber in mice,
resulting in enhancement of lipid metabolism. Thus, CLA supplementation might be a more
effective way to control skeletal muscle metabolism rather than exercise training alone.
In this study, the CLA-fed mice had an enhanced endurance capacity compared to the
control diet groups. Furthermore, 0.5% CLA supplementation combined with endurance training
showed a significant additional effect on the maximum running time and distance (Fig. 7.2).
These results are consistent with the previous studies that demonstrate increased maximum
swimming or running capacity in mice by CLA treatment 18,149,202-204. Indeed, three early studies
reported that 0.5% CLA supplemented mice increased voluntary movement (non-exercise
physical activity) 17,205,300. Although our results did not observe the overall CLA effect in
voluntary movement, the CLA-fed mice significantly traveled greater distances compared to
control-fed animals within the sedentary group. On the other hand, no CLA effect was observed
in the trained mice. This result is supported by a study where the trans-10,cis-12 CLA isomer
improved endurance capacity, while there were no changes in voluntary movement in the trained
mice 18. Ohnuki et al.148 also demonstrated no effect of a single oral administration of CLA on
locomotive activity. Thus, further studies with CLA are needed to discover the correlation
between voluntary movement and extensive endurance training.
It is known that endurance training activates various signaling cascades in skeletal
muscle energy metabolism. In particular, AMPK plays a central role in the adaptive response to
exercise, since AMPK senses lowered ATP levels due to increased energy demands by exercise,
which in turn leads to the activation of oxidative metabolism for energy homeostasis in the body
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301

. Our results demonstrated that the exercise trained groups had remarkably upregulated AMPK

phosphorylation levels in comparison to the sedentary animals, although other markers in the
down-stream signaling pathway of AMPK showed no alteration of their activities by overall
exercise effect. It might occur due to a bout of exercise with the same intensity and duration as
the training protocol before sacrifice. In fact, it has been reported that acute exercise enhanced
AMPK activities in skeletal muscle 302.
Adaptation in skeletal muscle includes the modulation of several transcriptional factors
in response to mitochondrial metabolism to promote lipid consumption as an energy source 303.
Specifically, PGC-1α acts as a key regulator in these transcriptional alterations, which regulates
mitochondrial and fatty acid metabolism 304. In these metabolic events, SIRT1 contributes to the
deacetylation of PGC-1α, and in turn controls its activity 305. In the same context, our data showed
that CLA supplementation activated SIRT1 expression in skeletal muscle, and up-regulated PGC1α (Fig. 7.3E and 7.3F). However, further studies are required to investigate how SIRT1 is
activated by CLA.
Mitochondrial biogenesis is a complex process that increases volume and changes
mitochondrial composition in response to physical and nutritional stimuli 219. Activated PGC-1α
triggers the modulation of nuclear and mitochondrial regulators such as PPARδ, NRF-1 and -2,
and Tfam, which are intimately linked to the stimulation of mitochondrial biogenesis 10. In the
current study, CLA supplementation sequentially facilitated PGC-1α, PPARδ and PGC-1α-NRF1-Tfam signaling cascades. Therefore, it suggests that CLA may potentiate mitochondrial
biogenesis. Although this study demonstrated the alteration in the biochemical markers of
mitochondrial biogenesis, it did not include a histological analysis, such as a visualization of
fluorescent mitochondria using dyes and microscopy, as well as the number of mitochondrial
DNA copies 228. Thus, further studies are needed in order to better understand the underlying
morphological changes of how CLA regulates mitochondrial biogenesis.

100

Along with PGC-1α, one of the key regulators in mitochondrial biogenesis and muscle
fiber type transformation is PPARδ. It is evident that PPARδ in skeletal muscle increases
mitochondria-rich oxidative type I fiber 3,191,192. In regards to skeletal muscle fibers, they are
briefly categorized into slow-twitch and fast-twitch, depending on their contractile properties 188.
The fiber in humans consists of myosin heavy chains (MHCs), which are segmented into MHC I,
MHC IIa and MHC IIx/d. These MHC isoforms have different characteristics: MHC I is an
oxidative slow-twitch type I fiber with a high density of mitochondria, which uses fatty acids as
the primary energy source; MHC IIx/d is a glycolytic fast-twitch type II fiber, using glucose and
phosphocreatine primarily to generate energy; MHC IIa is likely between type I and IIx/d 189. As
shown in the previous study 192, PPARδ could affect the regulation of muscle fiber type,
contributing to prolonged running endurance. In the present study, CLA-fed mice led to an
increase of PPARδ expression and the induction of overall MHC genes. Furthermore, CLA
supplementation significantly increased the gastrocnemius muscle mass (Table 7.2). Thus, it
suggests that CLA supplementation could affect the overall physiology of skeletal muscle based
on the PPARδ-driven metabolic events.
In regards to lipid metabolism, free fatty acids in plasma pass through a plasma
membrane in skeletal muscle by diffusion, or by transportation using receptor proteins such as
cluster of differentiation 36 (CD36), fatty acid binding protein (Fabp) and fatty acid transporter
protein 1 (FATP1), which in turn forms fatty acyl-CoA complexes. Subsequently, they enter
mitochondria by shuttling through CPT1 and then undergo oxidation 306. Our data demonstrated
that CLA significantly increased three key genes associated with lipid metabolism in skeletal
muscle, especially LPL, PPARα and CPT1β, which is consistent with the previous studies in mice
17,18,27,36,63,149

. Particularly, two studies among these elucidated to the effects of CLA

supplementation combined with endurance training on the alteration of molecular markers in
skeletal muscle lipid metabolism 18,149. Intriguingly, a number of transcriptional factors to control
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lipid metabolism are regulated by PPARδ in skeletal muscle, resulting in increased fatty acid βoxidation 257.
Furthermore, PPARδ targets genes in glucose and insulin metabolism. Increased PPARδ
induces phosphorylation of PDK, leading to the negative regulation of pyruvate dehydrogenase
complex (PDC). As a consequence, carbohydrate oxidation is reduced during fasting 193 .
However, results from the current study did not observe the overall effects of CLA or exercise in
PDK4 expression, although PPARδ protein levels were increased by CLA supplementation. Parra
et al.198 reported that CLA supplementation did not increase mRNA levels of PDK4, as well as
other genes associated with glucose and insulin metabolism. Increased GLUT4 expression in this
study is consistent with the previous observations 17,33,63. Therefore, our data suggest that CLA
supplementation may not inhibit glucose and insulin metabolism, but may promote lipid
metabolism.
Overall, CLA supplementation led to enhanced endurance capacity and positively
altered molecular markers in skeletal muscle metabolism, whereas exercise effects were limited
in this study. It might be derived from the heterogeneous factors in terms of the exercise protocols
such as intensity and duration. Although overall endurance exercise is known to induce
mitochondrial biogenesis and muscle fiber type transformation via the modulation of intracellular
biomarkers, it is not completely understood how the magnitude of exercise intensity and duration
influences these physiological and phenotypic alterations in skeletal muscle 307. In fact, Tadashi et
al.308 reported that PGC-1α expression levels were significantly correlated with the intensity of
running endurance in mice. In our study, we used a mixture of low-intensity and low-volume as
an exercise protocol. Thus, it could be suggested that increased endurance capacity under low
levels of exercise intensity and duration relies on CLA supplementation rather than exercise.
The potential health concerns related to CLA supplementation to date are glucose
intolerance and fatty liver 13,270,271. In the present study, we could not find any evidence in terms
of glucose intolerance associated with CLA supplementation. In fact, no significant increases in
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serum glucose levels were observed. However, more studies like glucose tolerance tests are
needed to confirm the influence of CLA in glucose intolerance. As reported in previous studies
17,18,152

, we observed an enlarged liver after CLA supplementation. It can be suggested that CLA

dramatically affects lipid metabolism, including reduced adipose tissue and increased hepatic
lipogenesis, resulting in the accumulation of TG in the liver. In the same context, the current
results showed decreased adipose tissue weight and serum TG levels in the CLA supplemented
mice (Table 7.2 and 7.3). Moreover, previous studies in rodents demonstrated no pathological
significance in the hepatic markers 269,295.
In conclusion, we demonstrated that CLA supplementation, yet not exercise alone,
promotes endurance capacity and increases skeletal muscle mass in this mouse model. It implies
that CLA supplementation is involved in skeletal muscle metabolism by stimulating
mitochondrial biogenesis and inducing muscle fiber gene expression, resulting in increased lipid
metabolism. Particularly, enhanced PPARδ-mediated signaling pathways regulate these metabolic
events. Although the precise mechanism of whether CLA regulates PPARδ directly or indirectly
was not dealt with this study, it is suggested that CLA exerts its action via the activation of PGC1α through SIRT1, subsequently leading to the up-regulation of PPARδ and its related target
markers in skeletal muscle. If further research on CLA supplementation is combined with an
appropriate exercise regime, with intensity and duration, it may provide a more effective method
to prevent obesity by the modulation of skeletal muscle metabolism.
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CHAPTER 8
CONCLUDING REMARKS

To date, calorie restriction and exercise are the most effective strategies to prevent
and/or reduce incidences of obesity. Nonetheless, there is an increasing prevalence of obesity due
to physical inactivity and sedentary lifestyle. Thus, various studies have been trying to find more
efficient prevention and treatment for obesity by understating the determinants contributing to
skeletal muscle and physical activity.
It is known that CLA reduces body fat and increases lean mass, resulting in the
alteration of body composition. While it is well established that CLA attenuates body fat
accumulation through the regulation of metabolism in adipocytes, the mechanisms of CLA on
skeletal muscle metabolism are not yet fully known. The objective of this proposed research was
to discover the underlying mechanism of how CLA modulates metabolism in skeletal muscle
based on the AMPK signaling pathway, and subsequent downstream signaling cascades.
In C2C12 murine skeletal muscle cells, both active CLA isomers (cis-9,trans-11 and
trans-10,cis-12) significantly activated PGC-1α, a master regulator of mitochondrial biogenesis,
via AMPKα phosphorylation in an isomer-specific manner. Subsequently, CLA isomers
enhanced PPARδ, NRF-1 and Tfam, which was needed to regulate mitochondrial biogenesis.
Consequently, CLA isomers increased the number of copies of mitochondrial DNA, mirrored by
enhanced mitochondrial biogenesis. It was suggested that CLA might act as an activator of
mitochondrial biogenesis in skeletal muscle.
In the genetically induced inactivity adult-onset obesity model (Nhlh2 gene knockout
mice), CLA supplementation prevented body weight gain and fat accretion by improved physical
activity. Specifically, CLA enhanced voluntary movement and increased skeletal muscle mass. It
is implied that CLA induced the physiological changes in skeletal muscle, supporting the
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activation of AMPKα, PGC-1α and downstream biomarkers related to mitochondrial biogenesis,
such as PPARδ and Tfam in CLA-fed mice. Thus, it might indicate that CLA treatment during the
developmental period in mice had a preventive effect on obesity caused by physical inactivity.
Next, we demonstrated that post-weaning CLA supplementation contributed to the
reduction of voluntary activity and glucose intolerance using the CLA withdrawal model in the
high-fat fed Nhlh2 mice. Although the genetically obese mice were not sufficient per se to
maintain health benefits by CLA supplementation during the pre-obese state, normal mice
showed significantly decreased body weight gain and fat mass along with increased physical
activity throughout the experiment. In particular, CLA-fed mice after withdrawal had improved
glucose homeostasis. These alterations in normal mice might be derived from the upregulation of
AMPKα and PPARδ, as well as the desensitization of PTEN and the sensitization of AKT at
threonine 308 in skeletal muscle. Thus, it could be suggested that the post-weaning administration
of CLA during the pre-obese state might partially stimulate the underlying molecular targets
involved in muscle metabolism in normal mice, yet not in the genetically induced inactive adultonset animal model.
Lastly, we elucidated to the effects of CLA supplementation and/or endurance exercise
on skeletal muscle metabolism. Results from this study demonstrated that CLA, but not lowlevels of exercise alone, promoted the maximum running time and distance along with increased
skeletal muscle mass. In addition, CLA supplementation stimulated mitochondrial biogenesisrelated factors through the activation of SIRT1 and PGC-1α in skeletal muscle. Of particular
importance, CLA increased the expression levels of PPARδ which is a key regulator of muscle
fiber type transformation. Consequently, CLA induced these molecular events such as
mitochondrial biogenesis and upregulated genes in muscle fibers, resulting in increased lipid
metabolism in skeletal muscle. It implied that CLA exerted its actions via the PPARδ-mediated
signaling pathway.
Collectively, CLA potentially acts as an exercise-mimetic, resulting in improved
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physical activity, which can support its function of regulating body fat.
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